substituted indoline derivatives as dengue viral replication inhibitors

专利摘要:
The present invention relates to substituted indoline derivatives, methods to prevent or treat viral dengue infections when using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral dengue infections. The present invention further relates to pharmaceutical compositions or combination preparations of the compounds, to compositions or preparations for use as a medicament, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparing the compounds.
公开号:BR112019024311A2
申请号:R112019024311-9
申请日:2018-05-18
公开日:2020-07-28
发明作者:Jean-François Bonfanti；Bart Rudolf Romanie Kesteleyn；Dorothée Alice Marie-Eve Bardiot；Arnaud Didier M. Marchand；Erwin Coesemans；Benoît Christian Albert Ghislain De Boeck；Pierre Jean-Marie Bernard Raboisson
申请人:Janssen Pharmaceuticals, Inc.；Katholieke Universiteit Leuven；
IPC主号:

专利说明:

[001] [001] The present invention relates to substituted indoline derivatives, with methods to prevent or treat viral infections of dengue when using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention relates moreover to pharmaceutical compositions or preparations for combining the compounds, with compositions or preparations for use as a medicament, most preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparing the compounds. BACKGROUND OF THE INVENTION
[002] [002] Flaviviruses, which are transmitted by mosquitoes or ticks, cause life-threatening infections in humans, such as headache and hemorrhagic fever. Four distinct but closely related serotypes of dengue flavivirus are known, so-called DENV-1, -2, -3 and -4. Dengue is endemic in most tropical and subtropical regions worldwide, predominantly in urban and semi-urban areas. According to the World Health Organization (WHO), 2.5 billion people, of which 1 billion children are at risk of DENV infection (WHO, 2002). 50 to 100 million estimated cases of dengue fever [DF], half a million cases of severe dengue disease (ie, dengue hemorrhagic fever [DHF] and dengue shock syndrome [DSS]), and more than 20,000 deaths occur globally each year. DHF has become a leading cause of hospitalization and death among children in endemic regions. Altogether, dengue represents the most common cause of arboviral disease. Due to large recent outbreaks in countries located in Latin America, Southeast Asia and the Western Pacific (including Brazil, Puerto Rico, Venezuela, Cambodia, Indonesia, Vietnam, Thailand), the numbers of dengue cases have increased dramatically over the past few years . Not only is the number of dengue cases increasing as the disease is spreading to new areas, but outbreaks also tend to be more serious.
[003] [003] After infection with another serotype, the pre-existing heterologous antibodies form complexes with the serotype of the newly infected denovirus but do not neutralize the pathogen. Instead, it is believed that virus entry into cells is facilitated, resulting in uncontrolled virus replication and higher peak viral titers. In both primary and secondary infections, higher viral titers are associated with more severe dengue disease. Since maternal antibodies can easily pass to breastfeeding children, this may be one of the reasons why children are more affected by severe dengue disease than adults.
[004] [004] In locations with two or more serotypes circulating simultaneously, also referred to as hyper-endemic regions, the risk of severe dengue disease is significantly higher due to an increased risk of experiencing a secondary, more serious infection. In addition, in a situation of hyperendemicity, the probability of the emergence of more virulent strains is increased, which in turn increases the probability of dengue haemorrhagic fever (DHF) or dengue shock syndrome.
[005] [005] Mosquitoes that carry dengue, including Aedes aegypti and Aedes albopictus (tiger mosquito), are moving north across the globe. According to the Centers for Disease Control and Prevention (CDC) in the United States (USA), both mosquitoes are currently ubiquitous in southern Texas. The spread to the north of mosquitoes carrying dengue is not confined to the USA, but has also been observed in Europe.
[006] [006] Dengvaxia®, the dengue vaccine produced by Sanofi Pasteur, was first approved in Mexico and has since received approval in more countries. Nevertheless, the vaccine leaves a lot of room for improvement due to its limited efficacy, especially against DENV-1 and -2, low efficacy in patients without previous treatment of flavivirus and the prolonged dosing schedule.
[007] [007] Despite these shortcomings, the vaccine is a major advance in endemic definitions, since it will offer protection to a large part of the population, but probably not to very young children, on whom the greatest incidence of dengue falls. In addition, the dosing schedule and the very limited efficacy in subjects without previous treatment of flavivirus make it inadequate and probably not compensatory / profitable for travelers from non-endemic areas to dengue-endemic areas. The aforementioned shortcomings of dengue vaccines are the reason why there is a need for a pre-exposure prophylactic dengue antiviral.
[008] [008] Furthermore, nowadays, no specific antiviral drugs are available for the treatment or prevention of infection by the dengue fever virus. Clearly, there is still a great unmet medical need for therapies for the prevention or treatment of viral infections in animals, more particularly in humans and especially for viral infections caused by flavivirus, more particularly Dengue virus. Compounds with good anti-viral potency, no or low levels of side effects, broad-spectrum activity against multiple Dengue virus serotypes, low toxicity and / or good pharmacokinetic properties or
[009] [009] WO-2010/021878 discloses 2-phenylpyrrolidine and indoline derivatives as cold menthol receptor antagonists for treating inflammatory and central diseases. WO-2013/045516 discloses indole and indoline derivatives for use in the treatment of viral dengue infections.
[0010] [0010] The present invention now provides compounds, substituted indoline derivatives, which show high potent activity against all four (4) serotypes of the Dengue virus. SUMMARY OF THE INVENTION
[0011] [0011] The present invention is based on the unexpected discovery that at least one of the problems mentioned above can be solved by the current compounds of the invention.
[0012] [0012] The present invention provides compounds that have been shown to have potent antiviral activity against all four (4) currently known serotypes. The present invention further demonstrates that these compounds efficiently inhibit the proliferation of the Dengue virus (DENV). Therefore, these compounds constitute a useful class of potent compounds that can be used in the treatment and / or prevention of viral infections in animals, mammals and humans, more specifically for the treatment and / or prevention of infections with Dengue virus.
[0013] [0013] The present invention further relates to the use of such compounds as medicines and their use for the manufacture of medicines for the treatment and / or prevention of viral infections, in particular with viruses belonging to the family of viruses of the Denounce in animals or mammals, more particularly in humans. The invention also relates to methods for the preparation of all such compounds and to pharmaceutical compositions comprising them in an effective amount.
[0014] [0014] The present invention also relates to a method of treating or preventing viral infections of dengue in humans by administering an effective amount of one or more such compounds, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more other drugs, such as another antiviral agent, to a patient in need.
[0015] [0015] The present invention relates to compounds of formula (I), including any stereochemically isomeric form thereof: R1 CH3
[0016] [0016] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is pentafluorosulfanyl, R5 is hydrogen, Z is carbon and R6 is hydrogen, or
[0017] [0017] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethyl, R5 is hydrogen, Z is carbon and R6 is methyl, or
[0018] [0018] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethyl, R5 is fluorine, Z is carbon and R6 is hydrogen, or
[0019] [0019] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is methyl, or
[0020] [0020] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is fluorine, Z is carbon and R6 is hydrogen, or
[0021] [0021] R1 is fluorine, R2 is methoxy, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is hydrogen, or
[0022] [0022] R1 is chlorine, R2 is hydrogen, R3 is deuterium, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is hydrogen, or
[0023] [0023] R1 is chlorine, R2 is -OCH2CH2OH, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is hydrogen, or
[0024] [0024] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethyl, R5 is methoxy, Z is nitrogen and R6 is absent, or
[0025] [0025] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-2) and R4 is trifluoromethyl, or
[0026] [0026] R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethylthio, R5 is hydrogen, Z is carbon and R6 is hydrogen;
[0027] [0027] or a pharmaceutically acceptable salt, solvate or polymorph thereof.
[0028] [0028] A first group of compounds of formula (I) consists of those compounds of formula (I) in which the radical A is (a-1).
[0029] [0029] A second group of compounds of formula (I) consists of those compounds of formula (I) in which the radical A is (a-2).
[0030] [0030] In an alternative embodiment, the present invention relates to a compound with the formula (I) R1 CH3
[0031] [0031] Part of the current invention is also a pharmaceutical composition comprising a compound mentioned above or a stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or vehicles.
[0032] [0032] The pharmaceutically acceptable salts of said compounds include the addition salts of acids and bases thereof. Suitable acid addition salts are formed from acids that form non-toxic salts. Suitable base salts are formed from bases that form non-toxic salts.
[0033] [0033] The pharmaceutically acceptable acid salts as mentioned above are intended to comprise the therapeutically active non-toxic acid addition salt forms that the compounds of formula (I) are capable of forming. These pharmaceutically acceptable acid addition salts can be conveniently obtained by treating the base form with such an appropriate acid. Suitable acids comprise, for example, inorganic acids such as hydrochloric acids, e.g., hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (ie, ethanedioic), malonic, succinic (ie, butanthioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfô - nico, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamenic, salicylic, p-aminosalicylic, pamoico and similar acids.
[0034] [0034] The compounds of the invention can also exist in unsolvated and solvated forms. The term "solvate" is used here to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
[0035] [0035] The term "polymorph" refers to the ability of the compound of the invention to exist in more than one crystal shape or structure.
[0036] [0036] The compounds of the present invention can be administered as crystalline or amorphous products. They can be obtained, for example, as solid buffers, powders or films by methods such as precipitation, crystallization, lyophilization, spray drying or evaporative drying. They can be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. They will generally be administered as a formulation in combination with one or more pharmaceutically acceptable excipients. The term "excipient" is used here to describe any ingredient other than the compound (s) of the invention. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability and the nature of the dosage form.
[0037] [0037] The compounds of the present invention or any subgroup thereof can be formulated in various dosage forms for administration purposes. As appropriate compositions, all compositions usually employed for systemic drug administration can be cited. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in the form of an addition salt, as the active ingredient is combined in admixture with a pharmaceutically acceptable carrier, which vehicle can take a wide variety in ways depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral or rectal administration. For example, in the preparation of compositions in oral dosage form, any of the usual pharmaceutical means such as, for example, water, glycols, oils, alcohols and the like can be employed in the case of liquid oral preparations such as suspensions, syrups , elixirs, emulsions, and solutions; or vehicle
[0038] [0038] It is especially advantageous to formulate the pharmaceutical compositions mentioned above in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including grooved or coated tablets), capsules, pills, powder packs, cachets, suppositories, injectable solutions and suspensions and the like and their multiple secretions.
[0039] [0039] Experts in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be 0.01 mg / kg to 50 mg / kg of body weight, more preferably 0.1 mg / kg to 10 mg / kg of body weight. It may be appropriate to administer the required dose as two, three, four or more underdoses at appropriate intervals throughout the day. Said underdoses can be formulated as unit dosage forms, for example, containing 1 to 1000 mg and, in particular, 5 to 200 mg of active ingredient per unit dosage form.
[0040] [0040] The exact dosage and frequency of administration depends
[0041] [0041] The present disclosure is also intended to include any isotopes of atoms present in the compounds of the invention. For example, hydrogen isotopes include tritium and deuterium and carbon isotopes include C-13 and C-14.
[0042] [0042] As used here, any chemical formula with bonds shown only as solid lines and not as solid wedged or perforated wedged bonds, or otherwise indicated as having a particular configuration (eg, R, S) in around one or more atoms, contemplate each possible stereoisomer, or mixture of two or more stereoisomers.
[0043] [0043] Formerly and henceforth, the terms "compound of the formula (I)" and "intermediates of the synthesis of the formula (I)" are intended to include the stereoisomers thereof and tautomeric forms thereof.
[0044] [0044] The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" previously or hereafter are used interchangeably.
[0045] [0045] The invention includes all stereoisomers of the compounds of the invention as pure stereoisomers or as a mixture of two or more stereoisomers. Enantiomers are stereoisomers that are non-overlapping images in each other's mirror. A mixture
[0046] [0046] The term "stereoisomers" also includes any rotamers, also called conformational isomers, that the compounds of formula (I) can form.
[0047] [0047] Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers, rotamers, and mixtures thereof, whenever chemically possible.
[0048] [0048] The meaning of all these terms, that is, enantiomers, diastereoisomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof is known to the skilled person.
[0049] [0049] The absolute configuration is specified according to the Cahn-Ingold-Prelog system. The configuration in an asymmetric atom is specified by R or S. The resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which the plane polarized light rotates. For example, resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which the plane of the polarized light rotates.
[0050] [0050] When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, that is, associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers. Thus, when a compound of formula (I) is specified for example as (R), this means that the compound is substantially free of the (S) isomer.
[0051] [0051] Some of the compounds according to formula (I) can also exist in their tautomeric form. Such forms, to the extent that they may exist, although not explicitly indicated in formula (I) above, are intended to be included in the scope of the present invention.
[0052] [0052] The compounds of formula (I) of the present invention have all at least one asymmetric carbon atom as indicated in the figure below by the carbon atom marked with *: R1 CH3
[0053] [0053] Due to the presence of said chiral center, a "compound of the formula (I)" can be the enantiomer (R), the enantiomer (S), the racemic form or any possible combination of the two individual enantiomers for any reason . When the (R) or (S) absolute configuration of an enantiomer is not known, this enantiomer can also be identified by indicating whether the enantiomer is dextrorotatory (+) - or levorotatory (-) - after measuring the rotation specific optics of that particular enantiomer.
[0054] [0054] In one aspect, the present invention relates to a first group of compounds of formula (I) in which the compounds of formula (I) have the specific rotation (+).
[0055] [0055] In a further aspect, the present invention relates to a second group of compounds of formula (I) in which the compounds of formula (I) have specific rotation (-). Examples LC / MS Methods
[0056] [0056] Measurement by High Performance Liquid Chromatography
[0057] [0057] The flow from the column was conducted to the Mass Spectrometer (MS) that was configured with an ion source at atmospheric pressure. It is within the knowledge of the expert to define the adjustment parameters (eg, scanning range, dwell time ...) in order to obtain ions allowing the identification of the nominal monoisotopic molecular weight (PM) of the compound. Data acquisition was performed with appropriate software.
[0058] [0058] The compounds are described by their retention times (Tr) and ions. If not specified differently in the data table, the reported molecular ion corresponds to [M + H] + (protonated molecule) and / or [M-H] - (deprotonated molecule). In case the compound was not directly ionizable, the type of adduct is specified (i.e., [M + NH4] +, [M + HCOO] -, etc ...). In the case of molecules with multiple isotopic patterns (Br, Cl), the reported value is that obtained for the lowest isotopic mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.
[0059] [0059] Hereinafter, "SQD" stands for Single Quadropole Detector, "MSD" Selective Mass Detector, "TA" at room temperature, "Ethyl siloxane / silica bridge hybrid", "DAD" Diodes Array Detector, "HSS "High Resistance silica.
[0060] [0060] LC / MS method codes (Flow expressed in mL / min; column temperature (T) in ° C; Operating time in minutes). Instrument Code Column Mobile phase LC-A method Waters: Acquity® UPLC® - Waters: BEH® C18 A: 95% CH3COONH4 DAD-Quattro MicroTM (1.7 µm, 2.1 x 100 mm) 7 mM / 5% CH3CN, B: CH3CN LC-B Waters: Acquity® Class H - Waters: BEH® C18 A: 95% CH3COONH4 DAD and SQD2TM (1.7 µm, 2.1 x 100 mm) 7 mM / 5% CH3CN ,
[0061] [0061] The measurement by SFC was performed using an Analytical chromatography system with Supercritical fluid (SFC) composed of a binary pump for administration of carbon dioxide (CO2) and modifier, a self-sampler, a column oven, an array detector diode equipped with a high pressure flow cell resisting up to 400 bar. If configured with a Mass Spectrometer (MS), the flow from the column was conducted to the (MS). It is within the knowledge of the expert to define the adjustment parameters (eg, scanning range, dwell time ...) in order to obtain ions allowing the identification of the nominal mono-isotopic molecular weight (PM) of the compound.
[0062] [0062] Data acquisition was performed with appropriate software. Analytical SFC / MS Methods (Flow expressed in mL / min;
[0063] [0063] The values are peak values or melting ranges and are obtained with experimental uncertainties that are commonly associated with this analytical method. DSC823e (indicated as DSC)
[0064] [0064] For a composite number, the melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 10 ° C / minute. The maximum temperature was 300 ° C. Optical Rotations:
[0065] [0065] Optical rotations were measured in a PerkinElmer 341 polarimeter with a sodium lamp and reported as follows: [α] º (λ, c g / 100 mL, solvent, T ° C).
[0066] [0066] [α] λT = (100α) / (lxc): where l is the path length in dm and c is the concentration in g / 100 mL for a sample at a temperature T (° C) and a wavelength λ (in nm). If the wavelength of light used is 589 nm (line D of sodium), then the symbol D could be used instead. The rotation sign (+ or -) must always be given. When using this equation, the concentration and solvent are always provided in parentheses after rotation. The rotation is reported using degrees and no concentration units are given (assumed to be g / 100 mL). Abbreviations used in the experimental part (M + H) + MH + protonated molecular ion iPrNH2 isopropylamine aq. aqueous iPrOH 2-propanol Boc tert-butyloxycarbonyl K2CO3 potassium carbonate Boc2O di-tert-butyl dicarbonate KNO3 potassium nitrate br broad LiAlH4 aluminum hydride and lithium CH3CN acetonitrile m / z mass to charge CHCl3 chloroform Me methyl CH2CH2CH2CH2CH2CH2CH2CH2 methanol CH3OH methanol MgSO4 magnesium sulfate CO2 carbon dioxide min minute (s) CsCO3 cesium carbonate MTBE double d methylene N2 nitrogen DCM dichloromethane Na2CO3 sodium carbonate DIEA diisopropylethylamine Na2SO4 sodium sulfate DIPE diisopropyl ether NaBH4 sodium borohydride DMA dimethylacetamide NaCl sodium chloride DMAP 4-dimethylaminopyridine NaHCO3 sodium bicarbonate
[0067] [0067] To a mechanically stirred solution of tert-butyl 4-bromo-butanoate [CAS 110661-91-1] (42.3 g, 0.19 mol) in DMF (600 mL) was added in portions a solid mixture of 3-amino-5-methoxyphenol [CAS 162155-27-3] (26.4 g, 0.19 mol) and Cs2CO3 (123.6 g,
[0068] [0068] At 0 ° C, BH3-Pyridine (1.46 mL, 14.5 mmol) was added slowly to a solution of 6- (pentafluoro-λ6-sulfanyl) -1H-indole [CAS 1379811-84-3] (1.0 g, 4.11 mmol) in EtOH (8.5 mL). 5N HCl (7 mL) was added slowly. The mixture was stirred at 0 ° C for 2 h and allowed to gradually warm to room temperature with stirring overnight. After cooling to 0 ° C (ice bath), 50% NaOH (2 ml) was added dropwise and stirring was continued for 15 min. Water (50 ml) was added and the product was extracted with 2/2 Et2O / EtOAc. The organic layer was separated, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (25 g) using a gradient of heptane / CH2Cl2 100/0 to 0/100. The product fractions were combined and evaporated under reduced pressure. The residue was dried under vacuum at 45 ° C, giving 6- (pentafluoro-λ6-sulfanyl) indoline 1b (328 mg). Synthesis of intermediate 1c:
[0069] [0069] A mixture of the determined 6- (pentafluoro-16-sulfanyl) indoline 1b (328 mg, 1.34 mmol), 2- (4-chlorophenyl) acetic acid [CAS 1878- 66-6] (228 mg , 1.34 mmol), HATU (778 mg, 2.0 mmol) and
[0070] [0070] At -70 ° C, under a flow of N2, 1 M LiHMDS in THF (1.78 mL, 1.78 mmol) was added dropwise to a mixture of 2- (4-chlorophenyl) -1- (6- (pentafluoro-λ6-sulfanyl) indolin-1-yl) ethanone 1c (354 mg, 0.89 mmol) in 2-Me-THF (35 mL) and the mixture was maintained at -70 ° C for 30 min TMSCl (182 µL, 1.42 mmol) was added dropwise. The mixture was stirred for 30 min at -70 ° C and a solution of N-bromosuccinimide (198 mg, 1.11 mmol) in a solvent mixture of THF (1.5 ml) and 2-Me-THF (5 ml ) was added dropwise. After stirring for 1 h at -78 ° C, the reaction was quenched with a saturated aqueous solution of NH4Cl (50 ml). The cooling bath was removed and the reaction mixture was stirred for 50 min. Water (10 mL) was added and the organic layer was separated, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure, giving 2-bromo-2- (4-chlorophenyl) -1- (6- (pentafluoro-λ6-sulfanil) indolin-1-yl) eta-
[0071] [0071] A mixture of 2-bromo-2- (4-chlorophenyl) -1- (6- (pentafluoro- λ6-sulfanyl) indolin-1-yl) ethanone 1d (424 mg, 0.89 mmol), 4- Tert-butyl (3-amino-5-methoxyphenoxy) butanoate 1a (260 mg, 0.92 mmol) and diisopropylethylamine (306 µL, 1.78 mmol) in CH3CN (30 mL) was stirred at 60 ° C for 18 h. The reaction mixture was allowed to reach room temperature and poured into water with stirring (150 ml). The product was extracted (2x) with Et2O. The combined organic layers were washed with brine, dried over MgSO4, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (40 g) using a gradient of liver / EtOAc / EtOH 100/0/0 to 40/45/15). The desired fractions were combined, evaporated under reduced pressure and coevaporated with dioxane.
[0072] [0072] The residue (602 mg, containing 58% of intermediate 1e) was mixed with 4 M HCl in dioxane (4 ml) and the mixture was stirred at room temperature for 5 h. The solids were removed by filtration, washed with dioxane (3x) and Et2O (2x) and dried under vacuum at 45 ° C, yielding 4- (3 - ((1- (4-chlorophenyl) -2-oxo- 2- (6- (penfluoro-λ6-sulfanyl) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butane crude (Compound 1, 309 mg). An analytical sample (60 mg) of racemic Compound 1 was further purified via preparative HPLC (Stationary phase: RP XBridge® Prep C18 OBD - 10 µm, 30 x 150 mm, mobile phase: 0.25% NH4HCO3 solution in water, CH3CN). The pure fractions were combined and the organic volatiles were evaporated under reduced pressure. The remaining aqueous solution was coevaporated under reduced pressure with o-xylene. The residue was dissolved in a solvent mixture of CH3CN and water, evaporated under reduced pressure and coevaporated with dioxane. The residue was lyophilized from a solvent mixture of CH3CN (2 mL) and water (0.8 mL), yielding 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2 acid - Pure (6- (pentafluoro-λ6-sulphonyl) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoic (Compound 1, 40 mg) as a powder.
[0073] [0073] The enantiomers of Compound 1 (249 mg) were separated by preparative chiral SFC (Stationary phase: Chiralpak® Diacel AD 20 x 250 mm, mobile phase: CO2, EtOH + 0.4% iPrNH2). The product fractions of the first eluted enantiomer were combined, evaporated under reduced pressure and coevaporated with MeOH. The residue was stirred in water (3.5 ml) and MeOH (1 ml), the solids were removed by filtration, washed (3x) with water / MeOH 4/1 and dried under vacuum at 45 ° C, giving rise Enantiomer 1A (41 mg). The product fractions of the second eluted enantiomer were combined, evaporated under reduced pressure and coevaporated with MeOH. The residue was stirred in water (3 ml) and MeOH (0.6 ml), the solids were removed by filtration, washed (3x) with water / MeOH 4/1 and dried under vacuum at 45 ° C, giving rise to the Enantiomer 1B (48 mg). Compound 1: 1
[0074] [0074] H NMR (400 MHz, DMSO-d6) δ ppm 1.86 (quin, J = 6.8 Hz, 2 H) 2.33 (t, J = 7.3 Hz, 2 H) 3.12 - 3.25 (m, 2 H) 3.61 (s, 3 H) 3.84 (t, J = 6.5 Hz, 2 H) 3.99 - 4.13 (m, 1 H) 4, 47 - 4.59 (m, 1 H) 5.57 (d, J = 8.6 Hz, 1 H) 5.76 (t, J = 2.1 Hz, 1 H) 5.91 - 5.96 (m, 2 H) 6.45 (d, J = 8.6 Hz, 1 H) 7.39 - 7.50 (m, 3 H) 7.51 - 7.62 (m, 3 H) 8, 58 (d, J = 2.0 Hz, 1 H) 12.12 (ls, 1 H)
[0075] [0075] LC / MS (LC-C method): Tr 1.09 min, MH + 621 1A enantiomer: 1
[0076] [0076] H NMR (360 MHz, DMSO-d6) δ ppm 1.85 (quin, J = 6.8 Hz, 2 H) 2.26 (tl, J = 6.8 Hz, 2 H) 3.15 - 3.25 (m, 2 H) 3.61 (s, 3 H) 3.84 (tl, J = 6.4 Hz, 2 H) 4.02 - 4.12 (m, 1 H) 4, 48 - 4.60 (m, 1 H) 5.59 (d, J = 8.8
[0077] [0077] LC / MS (LC-D method): Tr 1.99 min, MH + 621
[0078] [0078] [α] D20: -44.6 ° (c 0.28, DMF)
[0079] [0079] Chiral SFC (SFC-A method): Tr 3.54 min, MH + 621 chiral purity 97.9%. 1B Enantiomer: 1
[0080] [0080] H NMR (360 MHz, DMSO-d6) δ ppm 1.86 (quin, J = 6.8 Hz, 2 H) 2.33 (t, J = 7.3 Hz, 2 H) 3.14 - 3.29 (m, 2 H) 3.61 (s, 3 H) 3.84 (t, J = 6.4 Hz, 2 H) 4.01 - 4.11 (m, 1 H) 4, 48 - 4.58 (m, 1 H) 5.58 (d, J = 9.1 Hz, 1 H) 5.76 (t, J = 2.0 Hz, 1 H) 5.93 (t, J = 1.8 Hz, 1 H) 5.94 - 5.96 (m, 1 H) 6.48 (d, J = 9.1 Hz, 1 H) 7.41 - 7.48 (m, 3 H ) 7.52 - 7.61 (m, 3 H) 8.58 (d, J = 2.2 Hz, 1 H) 12.13 (ls, 1 H)
[0081] [0081] LC / MS (LC-D method): Tr 1.98 min, MH + 621
[0082] [0082] [α] D20: + 46.0 ° (c 0.265, DMF)
[0083] [0083] Chiral SFC (SFC-A method): Tr 3.82 min, MH + 621 99.0% chiral purity. Example 2: 4- (3 - ((1- (4-chlorophenyl) -2- (4-methyl-6- (trifluoromethyl) indolin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy acid synthesis ) butanoic (Compound 2) and chiral separation in Enantiomers 2A and 2B.
[0084] [0084] Pd / C (10%) (1.18 g) was added to a solution of 1-benzyl-4-methyl-6- (trifluoromethyl) indoline [CAS 1156512-79-6] (11.8 g, 40.5 mmol) in AcOH (11.8 mL) and MeOH (118 mL). The reaction was stirred at room temperature for 12 h under an atmosphere of H2. The mixture was filtered on a Celite® pad and concentrated under reduced pressure. The residue was collected with CH2Cl2, washed with water, brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (heptaine / EtOAc 9/1). The pure fractions were combined and the solvent was evaporated to dryness, yielding 8.2 g of 4-methyl-6- (trifluoromethyl) indoline 2a. Synthesis of intermediate 2b:
[0085] [0085] tert-Butyl 4- (3-Amino-5-methoxyphenoxy) butanoate 1a (2.94 g, 10.5 mmol) was added to the 2-bromo-2- (4-chlorophenyl) acetate solution methyl chloride [CAS 24091-92-7] (2.51 g, 9.53 mmol) in CH3CN (200 mL). Diisopropylethylamine (2.46 mL, 14.3 mmol) was added and the reaction mixture was stirred at 80 ° C overnight. The solvent was evaporated
[0086] [0086] Lithium hydroxide (336 mg, 14.0 mmol) was added to a solution of 4- (3 - ((1- (4-chlorophenyl) -2-methoxy-2-oxoethyl) amino) -5-methoxy - tert-butyl 2 nano) butanoate 2b (3.74 g, 7.02 mmol) in a mixture of water solvents (25 mL), MeOH (25 mL) and THF (75 mL) and the reaction mixture was stirred at room temperature for 5 h. Saturated aqueous NH4Cl (50 mL) was added and the organic volatiles were evaporated under reduced pressure. The residual aqueous solution was acidified with 1 N HCl to pH 2 and extracted twice with EtOAc. The combined organic layers were dried over MgSO4, filtered and evaporated under reduced pressure. The residue was dried under vacuum at 50 ° C, yielding 2 - ((3- (4- (tert-butoxy) -4-oxobutoxy) -5-methoxyphenyl) amino) -2- (4-chlorophenyl) ) acetic 2c (3.22 g) as a thick brown oil. Synthesis of intermediate 2d:
[0087] [0087] N, N-Di-isopropylethylamine (1.58 mL, 9.57 mmol) was added to a solution of 2 - ((3- (4- (tert-butoxy) -4-oxobutoxy) - acid 5- methoxyphenyl) amino) -2- (4-chlorophenyl) acetic 2c (1.44 g, 3.19) and 4-methyl-6- (trifluoromethyl) indoline 2a (953 mg, 3.51 mmol) in dry DMF (30 mL). HATU (1.82 g, 4.78 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was poured
[0088] [0088] 4- (3 - ((1- (4-Chlorophenyl) -2- (4-methyl-6- (trifluoromethyl) indolin-1-yl) - 2-oxoethyl) amino) -5-methoxyphenoxy) butanoate tert-butyl 2d (808 mg, 1.28 mmol) was mixed with 4 M HCl in dioxane (9.6 mL) and the mixture was stirred at room temperature for 15 h. Gaseous nitrogen was bubbled into the reaction mixture for 30 min. The solvent was evaporated under reduced pressure, yielding 4- (3 - ((1- (4-chlorophenyl) -2- (4-methyl-6- (trifluoromethyl) indolin-1-yl) -2-oxoethyl) acid amino) -5-methoxyphenoxy) butanoic (Compound 2, 735 mg) as a light brown solid.
[0089] [0089] The enantiomers of Compound 2 (735 mg) were separated by preparative chiral SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, mobile phase: CO2, EtOH + 0.4% iPrNH2). The product fractions were combined and evaporated under reduced pressure, giving rise to Enantiomer 2A as the first eluted product.
[0090] [0090] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin 1, J = 6.9 Hz, 2 H) 2.25 (s, 3 H) 2.33 (tl, J = 7 , 1 Hz, 2 H) 3.07 - 3.20 (m, 2 H) 3.62 (s, 3 H) 3.84 (tl, J = 6.4 Hz, 2 H) 3.97 - 4 .09 (m, 1 H) 4.48 - 4.60 (m, 1 H) 5.57 (dl, J = 8.8 Hz, 1 H) 5.76 (t, J = 1.8 Hz, 1 H) 5.90 - 5.99 (m, 2 H) 6.43 (dl, J = 8.8 Hz, 1 H) 7.25 (s, 1 H) 7.44 (d, J = 8 , 4 Hz, 2 H) 7.56 (dl, J = 8.4 Hz, 2 H) 8.22 (s, 1 H) 12.15 (ls, 1 H)
[0091] [0091] LC / MS (LC-C method): Tr 1.14 min, MH + 577 2A enantiomer: 1
[0092] [0092] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.8 Hz, 2 H) 2.25 (s, 3 H) 2.34 (t, J = 7, 3 Hz, 2 H) 3.05 - 3.23 (m, 2 H) 3.62 (s, 3 H) 3.85 (t, J = 6.4 Hz, 2 H) 4.03 (td, J = 10.2, 7.3 Hz, 1 H) 4.54 (td, J = 10.2, 6.2 Hz, 1 H) 5.57 (d, J = 8.8 Hz, 1 H) 5.76 (t, J = 2.0 Hz, 1 H) 5.91 - 5.99 (m, 2 H) 6.42 (d, J = 8.8 Hz, 1 H) 7.24 (s , 1 H) 7.44 (d, J = 8.4 Hz, 2 H) 7.56 (d, J = 8.8 Hz, 2 H) 8.22 (s, 1 H) 12.17 (sl , 1H)
[0093] [0093] LC / MS (LC-C method): Tr 1.26 min, MH + 577
[0094] [0094] [α] D20: -39.0 ° (c 0.438, DMF)
[0095] [0095] Chiral SFC (SFC-B method): Tr 5.11 min, MH + 577 chiral purity 100%. 2B Enantiomer: 1
[0096] [0096] H NMR (360 MHz, DMSO-d6) δ ppm 1.88 (quin, J = 6.9 Hz, 2 H) 2.25 (s, 3 H) 2.34 (t, J = 7, 3 Hz, 2 H) 3.06 - 3.24 (m, 2 H) 3.62 (s, 3
[0097] [0097] LC / MS (LC-C method): Tr 1.25 min, MH + 577
[0098] [0098] [α] D20: + 47.1 ° (c 0.384, DMF)
[0099] [0099] Chiral SFC (SFC-B method): Tr 8.00 min, MH + 577 chiral purity 99.6%. Example 3: 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy acid synthesis ) butanoic (Compound 3) and chiral separation in Enantiomers 3A and 3B.
[00100] [00100] At 0 ° C, BH3-Pyridine (10.45 mL, 103.4 mmol) was added slowly to a solution of 5-fluoro-6- (trifluoromethyl) -1H-indole [CAS 1493800-10-4] (7.0 g, 34.5 mmol) in EtOH (45 mL). 6 N HCl (105 mL) was added dropwise keeping the temperature below 10 ° C. The mixture was stirred at 0 ° C for 3 h. Water was added and the mixture was basified to pH 8.5 with a concentrated solution of NaOH (temperature less than 20 ° C). EtOAc was added. The organic layer was separated, washed with water, dried over MgSO4, filtered, and the solvent evaporated under reduced pressure. Toluene was added
[00101] [00101] A mixture of 5-fluoro-6- (trifluoromethyl) indoline 3a (500 mg, 2.44 mmol), 2- (4-chlorophenyl) acetic acid [CAS 1878-66-6] (457 mg, 2, 64 mmol), HATU (1.39 g, 3.66 mmol) and diisopropylethylamine (1.2 mL, 7.31 mmol) in DMF (10 mL) was stirred at room temperature for 12 h. The mixture was poured into ice water, the precipitate was removed by filtration and collected with CH2Cl2. The organic layer was dried over MgSO4 and concentrated under reduced pressure. The compound was crystallized from CH3CN and dried, yielding 2- (4-chlorophenyl) -1- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) ethanone 3b (854 mg). Synthesis of intermediate 3c:
[00102] [00102] At -78 ° C, under a flow of N2, 1 M LiHMDS in THF (4.78 mL, 4.78 mmol) was added dropwise to a mixture of 2- (4-chlorophenyl) -1- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) ethanone 3b (854 mg, 2.39 mmol) in THF (7 mL). TMSCl (485 µL, 3.82 mmol) was added dropwise. The mixture was stirred for 15 min at -78 ° C and a solution of N-bromosuccinimide (510 mg, 2.87 mmol) in THF (7 ml) was added dropwise. After stirring for 2 h at -78 ° C, the reaction was quenched with a saturated aqueous solution of NH4Cl. EtOAc was added and the organic layer was separated, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 µm, 40 g, CH2Cl2 / 50/50 heptane). The pure fractions were combined and the solvent was concentrated under reduced pressure, giving 2-bromo- 2- (4-chlorophenyl) -1- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) ethanone 3c (820 mg). Synthesis of intermediate 3d:
[00103] [00103] A mixture of 2-bromo-2- (4-chlorophenyl) -1- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) ethanone 3c (820 mg, 1.88 mmol), 4- Tert-butyl (3-amino-5-methoxyphenoxy) -butanoate 1a (528 mg, 1.88 mmol) and diisopropylethylamine (388 µL, 2.25 mmol) in CH3CN (20 mL) was stirred at 70 ° C for 4 h. The reaction mixture was concentrated under reduced pressure. The residue was taken up with EtOAc. The organic layer was washed twice with a 1 N solution of HCl, water, dried over MgSO4, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 µm, 40 g, 100% CH2Cl2). The pure fractions were combined and the solvent was concentrated under reduced pressure, yielding 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) Tert-butyl -2-oxoethyl) amino) -5-methoxyphenoxy) -butanoate 3d (1.07 g). Synthesis of Compound 3 and chiral separation in Enantiomers 3A and 3B:
[00104] [00104] A solution of 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethyl) indolin-1-yl) -2-oxoethyl) amino) -5 tert-butyl methoxyphenoxy) butanoate 3d (1.07 g, 1.68 mmol) in HCl (4 M in dioxane) (20 mL) was stirred at 5 ° C for 3 h and at room temperature for 12 h. The precipitate was removed by filtration, washed with diisopropyl ether and dried. The residue was purified via reverse phase chromatography (Stationary phase: YMC-actus Triart-C18 10 µm 30 x 150 mm, mobile phase: gradient from 65% NH4HCO3 to 0.2%, 35% CH3CN to 25% NH4HCO3 0.2%, 75% CH3CN), giving Compound 3 (540 mg). An analytical sample (30 mg) was further purified via reverse phase chromatography (Stationary phase: YMC-actus Tri-art-C18 10 µm 30 x 150 mm, mobile phase: gradient from 65% NH4HCO3 to 0.2, 35% CH3CN up to 25% NH4HCO3 0.2%, 75%
[00105] [00105] H NMR (500 MHz, DMSO-d6) δ ppm 1.78 - 1.92 (m, 2 H) 2.26 (ls, 2 H) 3.15 - 3.31 (m, 2 H) 3.61 (s, 3 H) 3.84 (ls, 2 H) 4.02 (dl, J = 7.88 Hz, 1 H) 4.54 (dl, J = 5.99 Hz, 1 H) 5.58 (dl, J = 8.51 Hz, 1 H) 5.76 (ls, 1 H) 5.90 - 5.99 (m, 2 H) 6.42 (dl, J = 8.51 Hz , 1 H) 7.44 (dl, J = 7.88 Hz, 3 H) 7.55 (dl, J = 7.88 Hz, 2 H) 8.38 (dl, J = 6.31 Hz, 1 H) 11.60 - 12.92 (m, 1 H)
[00106] [00106] LC / MS (LC-A method): Tr 2.94 min, MH + 581
[00107] [00107] Melting point: 206 ° C 3A enantiomer: 1
[00108] [00108] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.86 Hz, 2 H) 2.29 - 2.39 (m, 2 H) 3.18 - 3, 30 (m, 2 H) 3.62 (s, 3 H) 3.85 (t, J = 6.46 Hz, 2 H) 4.03 (td, J = 10.25, 7.25 Hz, 1 H) 4.54 (td, J = 10.17, 6.15 Hz, 1 H) 5.58 (d, J = 8.51 Hz, 1 H) 5.76 (s, 1 H) 5.95 (dl, J = 11.35 Hz, 2 H) 6.43 (d, J = 8.83 Hz, 1 H) 7.43 - 7.48 (m, 3 H) 7.55 (d, J = 8.51 Hz, 2 H) 8.39 (d, J = 6.31 Hz, 1 H) 12.08 - 12.27 (m, 1 H)
[00109] [00109] LC / MS (LC-A method): Tr 2.95 min, MH + 581
[00110] [00110] [α] D20: -48.9 ° (c 0.315, DMF)
[00111] [00111] Chiral SFC (SFC-G method): Tr 1.65 min, MH + 581 100% chiral purity. 3B Enantiomer: 1
[00112] [00112] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.54 Hz, 2 H) 2.25 - 2.46 (m, 2 H) 3.15 - 3, 31 (m, 2 H) 3.62 (s, 3 H) 3.85 (tl, J = 6.31 Hz, 2 H) 3.98 - 4.07 (m, 1 H) 4.50 - 4 .59 (m, 1 H) 5.58 (dl, J = 8.83 Hz, 1 H) 5.76 (s, 1 H) 5.95 (dl, J = 12.30 Hz, 2 H) 6 , 43 (dl, J = 8.83 Hz, 1 H) 7.42 - 7.48 (m, 3 H) 7.56 (dl, J = 8.20 Hz, 2 H) 8.39 (dl, J = 6.31 Hz, 1 H) 11.40 - 12.54 (m, 1 H)
[00113] [00113] LC / MS (LC-A method): Tr 2.94 min, MH + 581
[00114] [00114] [α] D20: + 47.8 ° (c 0.27, DMF)
[00115] [00115] Chiral SFC (SFC-G method): Tr 2.14 min, MH + 581 chiral purity 99.43%. Example 4: 4- (3 - ((1- (4-chlorophenyl) -2- (4-methyl-6- (trifluoromethoxy) indolin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy acid synthesis ) butanoic (Compound 4) and chiral separation in Enantiomers 4A and 4B.
[00116] [00116] To a solution of 2-methyl-4- (trifluoromethoxy) aniline [CAS 86256-59-9] (10.0 g, 52.3 mmol) in dioxane (20 mL) was added trifluoroacetic anhydride (8 mL, 57.2 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc and 1 N HCl. The phases were separated. The organic phase was washed with a saturated solution of NaHCO3 in water, H2O and saturated aqueous sodium chloride solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give 14.7 g of 2.2.2 -trifluoro-N- (2-methyl-4- (trifluoromethoxy) phenyl) acetamide 4a as a white powder. The compound was used in the next step without further purification. Synthesis of intermediate 4c:
[00117] [00117] To acetic anhydride (11.4 ml, 61.1 mmol), cooled to 0 ° C, 70% nitric acid (3.9 ml) was added dropwise. 2,2,2-Trifluoro-
[00118] [00118] To a solution of 2-methyl-6-nitro-4- (trifluoromethoxy) aniline 4c (1.8 g, 7.69 mmol) in acetic acid (10.9 mL) was added dropwise a solution of sodium nitrite (0.806 g, 11.7 mmol) in H2SO4 / H2O (2 mL, 1/1). The reaction mixture was stirred at room temperature for 30 min. H2O (22 mL) and urea (0.802 g, 13.4 mmol) were added. After 10 min at room temperature, a solution of potassium iodide (1.7 g, 10.2 mmol) in H2O (11 mL) was added dropwise. The reaction mixture was stirred at room temperature for 30 min. The yellow solid was removed by filtration, washed with H2O and dried to give 2.4 g of 2-iodo-1-methyl-3-nitro-5- (trifluoromethoxy) benzene 4d. Synthesis of intermediate 4e:
[00119] [00119] To a solution of 2-iodo-1-methyl-3-nitro-5- (trifluoromethoxy) benzene 4d (3.5 g, 10.0 mmol) in EtOH (30 mL) was added a solution of NH4Cl ( 2.7 g, 49.9 mmol) in H2O (30 mL). The reaction mixture was heated to 50 ° C. Iron (2.6 g, 46.9 mmol) was added and the reaction mixture was heated to reflux for 40 min. After cooling to room temperature, the reaction mixture was filtered through Celite®. The solids were washed with EtOH. The filtrate was partially concentrated under reduced pressure to remove EtOH. The residue was partitioned between EtOAc and a saturated solution of NaHCO3 in water. The phases were separated. The organic phase was washed with H2O and saturated aqueous sodium chloride solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (0% to 25%) in heptane to give 2.9 g of 2-iodo-3-methyl-5- (trifluoromethoxy) aniline 4e as a yellow oil. Synthesis of intermediate 4f:
[00120] [00120] A solution of 2-iodo-3-methyl-5- (trifluoromethoxy) aniline 4e (2.9 g, 9.1 mmol) in triethylamine (23 mL) was degassed with argon for 15 min. Dichlorobis (triphenylphosphine) palladium (II) (0.327 g, 0.47 mmol), copper (I) iodide (0.164 g, 0.86 mmol) and trimethylsilylacetylene (1.8 mL, 13.1 mmol) were added ). The reaction mixture was heated to 65 ° C for 12 h. After cooling to room temperature, the reaction mixture was diluted with H2O and extracted with EtOAc (3x). The organic phases were combined, washed with H2O and brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (0% to 20%) in heptane to give 2.6 g of 3-methyl-5- (trifluoromethoxy) -2 - ((trimester) tilsili) ethinyl) aniline 4f as an orange oil. Synthesis of intermediate 4g:
[00121] [00121] To a solution of 3-methyl-5- (trifluoromethoxy) -2 - ((trimethylsilyl) ethynyl) aniline 4f (2.7 g, 9.3 mmol) in NMP (27 mL) was added tBu- OK ( 3.1 g, 27.8 mmol). The reaction mixture was heated to 80 ° C for 4 h. After cooling to room temperature, the reaction mixture was diluted with H2O and extracted with EtOAc (2x). The organic phases were combined, washed with H2O and brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (0% to 20%) in heptane to give 1.7 g of 4-methyl-6- (trifluoromethoxy) -1H-indole 4g as an orange oil . Synthesis of intermediate 4h:
[00122] [00122] At 0 ° C, BH3-Pyridine (1.2 mL, 11.6 mmol) was added dropwise to a solution of 4-methyl-6- (trifluoromethoxy) -1H-indole 4g (0.5 g , 2.32 mmol) in EtOH (3 mL). 6 N HCl (6 mL) was slowly added dropwise while maintaining the reaction temperature below 10 ° C. The mixture was stirred at 0 ° C for 3 h. Water (12 ml) was added and the mixture was basified to pH 8-9 with a concentrated solution of NaOH in water (the reaction temperature was kept below 20 ° C). The mixture was extracted with EtOAc. The organic layer was washed with water, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. Toluene was added and the solution was concentrated under reduced pressure to give 450 mg of 4-methyl-6- (trifluoromethoxy) indoline 4h. Synthesis of intermediate 4i:
[00123] [00123] N, N-Di-isopropylethylamine (1.58 mL, 9.57 mmol) was added to a solution of 2 - ((3- (4- (tert-butoxy) -4-oxobutoxy) - acid 5- methoxyphenyl) amino) -2- (4-chlorophenyl) acetic 2c (1.44 g, 3.19) and 4-methyl-6- (trifluoromethoxy) indoline 4h (846 mg, 3.51 mmol) in dry DMF (30 mL). HATU (1.82 g, 4.78 mmol) was added and the reaction mixture was stirred
[00124] [00124] 4- (3 - ((1- (4-Chlorophenyl) -2- (4-methyl-6- (trifluoromethoxy) indolin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy) butanoate tert-butyl 4i (821 mg, 1.27 mmol) was mixed with 4 M HCl in dioxane (9.5 mL) and the mixture was stirred at room temperature for 15 h. Gaseous nitrogen was bubbled into the reaction mixture for 30 min. The solvent was evaporated under reduced pressure, yielding 4- (3 - ((1- (4-chlorophenyl) -2- (4-methyl-6- (trifluoromethyl) indolin-1-yl) -2-oxoethyl) acid amino) -5-me-toxifenoxy) butanoic (Compound 4, 750 mg) as an off-white solid.
[00125] [00125] Compound 4 enantiomers (750 mg) were separated by preparative chiral SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, mobile phase: CO2, EtOH + 0.4% iPrNH2). The product fractions were combined and evaporated under reduced pressure.
[00126] [00126] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 7.0 Hz, 2 H) 2.20 (s, 3 H) 2.33 (t, J = 7, 1 Hz, 2 H) 2.98 - 3.16 (m, 2 H) 3.61 (s, 3 H) 3.84 (t, J = 6.4 Hz, 2 H) 4.04 (td, J = 10.4, 7.0 Hz, 1 H) 4.53 (td, J = 10.3, 6.4 Hz, 1 H) 5.56 (d, J = 9.1 Hz, 1 H) 5.76 (t, J = 2.0 Hz, 1 H) 5.91 - 5.98 (m, 2 H) 6.45 (d, J = 8.8 Hz, 1 H) 6.87 (s , 1 H) 7.38 - 7.47 (m, 2 H) 7.50 - 7.61 (m, 2 H) 7.89 (s, 1 H) 12.18 (ls, 1 H)
[00127] [00127] LC / MS (LC-C method): Tr 1.14 min, MH + 593 4A enantiomer: 1
[00128] [00128] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.9 Hz, 2 H) 2.20 (s, 3 H) 2.34 (t, J = 7, 3 Hz, 2 H) 2.98 - 3.16 (m, 2 H) 3.62 (s, 3 H) 3.85 (t, J = 6.4 Hz, 2 H) 4.05 (td, J = 10.4, 7.0 Hz, 1 H) 4.53 (td, J = 10.3, 6.4 Hz, 1 H) 5.56 (d, J = 8.8 Hz, 1 H) 5.76 (t, J = 1.8 Hz, 1 H) 5.91 - 5.99 (m, 2 H) 6.45 (d, J = 8.8 Hz, 1 H) 6.88 (s , 1 H) 7.38 - 7.49 (m, 2 H) 7.51 - 7.61 (m, 2 H) 7.89 (s, 1 H) 12.17 (ls, 1 H)
[00129] [00129] LC / MS (LC-C method): Tr 1.29 min, MH + 593
[00130] [00130] [α] D20: -39.6 ° (c 0.455, DMF)
[00131] [00131] Chiral SFC (SFC-C method): Tr 3.34 min, MH + 593 100% chiral purity. 4B Enantiomer: 1
[00132] [00132] H NMR (360 MHz, DMSO-d6) δ ppm 1.88 (quin, J = 6.9 Hz,
[00133] [00133] LC / MS (LC-C method): Tr 1.30 min, MH + 593
[00134] [00134] [α] D20: + 43.7 ° (c 0.38, DMF)
[00135] [00135] Chiral SFC (method SFC-C method): Tr 3.16 min, MH + 593 chiral purity 100%. Example 5: 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethoxy) indolin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy acid synthesis ) butanoic (Compound 5) and chiral separation in Enantiomers 5A and 5B.
[00136] [00136] A solution of 4-bromo-2-fluoro-1- (trifluoromethoxy) benzene [CAS 105529-58-6] (98.7 g, 381.1 mmol) in concentrated H2SO4 (98%, 200 mL ) was cooled to 0 ° C with an ice bath. KNO3 (43.0 g, 425.3 mmol) was added in portions. After addition, the ice bath was removed and the mixture was stirred at room temperature for 16 h. The reaction mixture was poured into ice water (2 L) while stirring. The mixture was extracted with CH2Cl2 (3 x 500 ml). The combined organic layers were washed with a saturated aqueous solution of NaHCO3 (2x 500 mL), brine (500 mL), dried over MgSO4, filtered and concentrated under reduced pressure to give 1-bromo-5-fluoro-2-nitro -4- (trifluoromethoxy) benzene 5a (117.2 g), which was used in the next step without further purification. Synthesis of intermediate 5b:
[00137] [00137] To a stirred suspension of 1-bromo-5-fluoro-2-nitro-4- (trifluoromethoxy) benzene 5a (70.0 g, 230 mmol) and NH4Cl (123.2 g, 2.30 mol) in iPrOH (1 L) and water (330 mL) reducing iron powder (64.3 g, 1.15 mol) was added under N2 atmosphere. The reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was diluted with EtOAc (1 L) and filtered through Celite®. The filtrate was concentrated under reduced pressure. The residue was partitioned between EtOAc (1 L) and water (800 ml). The layers were separated and the organic phase was washed with brine (1 L), dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by distillation under reduced pressure (oil pump, e.g. 60 ~ 64 ° C). 2-Bromo-4-fluoro-5- (trifluoromethoxy) aniline 5b (47.3 g) was obtained as a yellow oil. Synthesis of intermediate 5c:
[00138] [00138] To a mixture of 2-bromo-4-fluoro-5- (trifluoromethoxy) aniline 5b (18.4 g, 67.2 mmol), ethinyl (trimethyl) silane (19.9 g, 202.4 mmol, 28.00 ml) in Et3N (300 ml) CuI (1.28 g, 6.72 mmol) and Pd (PPh3) 2Cl2 (2.40 g, 3.42 mmol) were added. The reaction mixture was heated under an N2 atmosphere at 90 ° C for 16 h. After cooling to room temperature, the mixture was diluted with MTBE (300 mL) and filtered through Celite®. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (ISCO®, 220 g SepaFlash® Silica Flash Column, eluent: EtO-
[00139] [00139] A mixture of 4-fluoro-5- (trifluoromethoxy) -2 - ((trimethylsilyl) ethynyl) aniline 5c (16.1 g, 55.3 mmol) and tBuOK (18.6 g, 165.8 mmol) in NMP (220.00 ml) it was heated to 90 ° C for 16 h under N2 atmosphere. After cooling to room temperature, the reaction mixture was poured into ice water (1 L) and extracted with MTBE (3 x 300 ml). The combined organic phases were washed with water (2 x 200 ml), brine (300 ml), dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (ISCO®, Column of 120 g SepaFlash® Silica Flash, eluent: gradient from 0 to 5% EtOAc in petroleum ether @ 85 mL / min) to give 5-fluoro product -6- (trifluoromethoxy) -1H-indole 5d (11 g) as a dark green oil. The residue was combined with another fraction (total amount = 17.2 g) and further purified by distillation under reduced pressure (oil pump, eg 60 ~ 64 ° C), giving rise to 5-fluoro-6- (trifluoromethoxy) - 1H-indole 5d (14.7 g, 95% purity) as a colorless oil. Synthesis of intermediate 5e:
[00140] [00140] At 0 ° C, BH3-pyridine (13.8 mL, 136.9 mmol) was added dropwise to a solution of 5-fluoro-6- (trifluoromethoxy) -1H-indole 5d (6 g, 27 , 4 mmol) in EtOH (40 mL). 6N HCl (90 mL) was added dropwise while maintaining the temperature below 10 ° C. The mixture was stirred at 0 ° C for 2 h. Water (100 ml) was added and the mixture was basified to pH 8-9 with a concentrated solution of NaOH in water (the reaction temperature was kept below 20 ° C). The mixture was extracted with CH2Cl2. The organic layer was washed with water, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. Toluene was added and the solution was concentrated under reduced pressure to give 5.52 g of 5-fluoro-6- (trifluoromethoxy) indoline 5e. The compound was used in the next reaction step without further purification. Synthesis of intermediate 5f:
[00141] [00141] To a mixture of 2-bromo-2- (4-chlorophenyl) acetic acid [CAS 3381-73-5] (0.61 g, 2.4 mmol), 5-fluoro-6- (trifluoromethoxy) indoli - in 5e (0.55 g, 2.2 mmol) and DMAP (0.027 g, 0.22 mmol) in CH2Cl2 (14 mL) EDCI (0.51 g, 2.7 mmol) was added. The mixture was stirred at room temperature for 18h. The mixture was diluted with a 10% K2CO3 solution in water. The layers were decanted. The organic layer was washed with water, dried over MgSO4, filtered and the solvent was concentrated under reduced pressure to give 2-bromo-2- (4-chlorophenyl) -1- (5-fluoro-6- (trifluoromethoxy) indolin-1 -il) ethanone 5f (1.1 g, purple oil). The compound was used in the next step without further purification. Synthesis of intermediate 5g:
[00142] [00142] A mixture of 2-bromo-2- (4-chlorophenyl) -1- (5-fluoro-6- (trifluoromethoxy) indolin-1-yl) ethanone 5f (1.1 g, 2.2 mmol ), Tert-butyl 4- (3-amino-5-methoxyphenoxy) butanoate 1a (1.0 g, 3.3 mmol) and diisopropylethylamine (1.5 mL, 8.7 mmol) in CH3CN (29 mL ) was stirred at 80 ° C for 18 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (30 µm, 40 g, heptane / EtOAc gradient 85/15 to 75/25). The fractions containing the expected compound were combined and the solvent was concentrated under reduced pressure, yielding 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethoxy) indolin-1 -il) -2-oxoethyl) amino) -5-methoxyphenoxy) tert-butyl butanoate 5g (480 mg, 57% purity by LC / MS). Synthesis of Compound 5 and chiral separation in Enantiomers 5A and
[00143] [00143] A mixture of 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethoxy) indolin-1-yl) -2-oxoethyl) amino) -5 tert-butyl methoxyphenoxy) butanoate 5g (0.48 g, 0.42 mmol, 57% purity) in HCl (4 M in dioxane) (4.6 mL) was stirred at room temperature for 18 h. The mixture was concentrated under reduced pressure, collected in Et 3 N (5 ml) and concentrated again in vacuo. The residue was purified by flash chromatography on silica gel (30 µm, 24 g, CH2Cl2 / MeOH gradient 99/1 to 96/4). The pure fractions were combined and evaporated to dryness. The residue (150 mg) was further purified via Reverse Phase HPLC (Stationary phase: YMC-actus Triart-C18 10 µm 30 x 150 mm, mobile phase: gradient from 65% NH4HCO3 to 0.2%, 35% CH3CN up to 25% 0.2% NH4HCO3, 75% CH3CN), giving rise to 4- (3 - ((1- (4-chlorophenyl) -2- (5-fluoro-6- (trifluoromethoxy) acid indolin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy) butanoic (Compound 5, 71 mg). The enantiomers (55 mg) were separated via chiral SFC (Stationary phase: Chiralcel® OD-H 5 µm 250 x 20 mm, mobile phase: 55% CO2, 45% MeOH), giving rise, after freeze-drying from a mixture of CH3CN / water solvents, the first eluted Enantiomer 5A (25 mg, white solid) and the second eluted Enantiomer 5B (25 mg, white solid). Compound 5: 1
[00144] [00144] H NMR (500 MHz, DMSO-d6) δ ppm 1.86 (quin, J = 6.70 Hz, 2 H) 2.24 - 2.43 (m, 2 H) 3.06 - 3, 25 (m, 2 H) 3.61 (s, 3H) 3.84 (tl, J = 6.31 Hz, 2 H) 3.94 - 4.13 (m, 1 H) 4.46 - 4, 57 (m, 1 H) 5.56 (dl, J = 8.83 Hz, 1 H) 5.75 (s, 1 H) 5.93 (s, 1 H) 5.95 (s, 1 H) 6.45 (dl, J = 8.83 Hz, 1 H) 7.44 (dl, J = 8.20 Hz, 3 H) 7.54 (dl, J = 8.20 Hz, 2 H) 8, 16 (dl, J = 6.62 Hz, 1 H) 12.12 (ls, 1H)
[00145] [00145] LC / MS (LC-A method): Tr 3.00 min, MH + 597 Enantiomer 5A:
[00146] [00146] H NMR (500 MHz, DMSO-d6) δ ppm 1.86 (quin, J = 6.94 Hz, 2 H) 2.25 - 2.44 (m, 2 H) 3.06 - 3, 26 (m, 2 H) 3.61 (s, 3 H) 3.84 (t, J = 6.46 Hz, 2 H) 4.05 (td, J = 10.32, 7.09 Hz, 1 H) 4.48 - 4.55 (m, 1 H) 5.56 (d, J = 8.83 Hz, 1 H) 5.76 (t, J = 1.89 Hz, 1 H) 5.94 (dl, J = 11.98 Hz, 2 H) 6.45 (d, J = 8.83 Hz, 1 H) 7.42 - 7.46 (m, 3 H) 7.54 (d, J = 8.20 Hz, 2 H) 8.16 (dl, J = 6.94 Hz, 1 H) 12.01 (ls, 1H)
[00147] [00147] LC / MS (LC-A method): Tr 3.00 min, MH + 597
[00148] [00148] [α] D20: -35.8 ° (c 0.257, DMF)
[00149] [00149] Chiral SFC (SFC-H method): Tr 1.34 min, MH + 597 100% chiral purity. 5B Enantiomer: 1
[00150] [00150] H NMR (500 MHz, DMSO-d6) δ ppm 1.85 (quin, J = 6.86 Hz, 2 H) 2.27 (t, J = 7.25 Hz, 2 H) 3.10 - 3.31 (m, 2 H) 3.61 (s, 3 H) 3.78 - 3.90 (m, 2 H) 4.05 (td, J = 10.40, 7.25 Hz, 1 H) 4.52 (td, J = 10.32, 6.46 Hz, 1 H) 5.57 (d, J = 8.83 Hz, 1 H) 5.75 (t, J = 1.89 Hz , 1 H) 5.94 (dl, J = 16.39 Hz, 2 H) 6.45 (d, J = 8.83 Hz, 1 H) 7.41 - 7.46 (m, 3 H) 7 , 55 (d, J = 8.51 Hz, 2 H) 8.16 (dl, J = 6.94 Hz, 1 H)
[00151] [00151] LC / MS (LC-A method): Tr 3.00 min, MH + 597
[00152] [00152] [α] D20: + 52.8 ° (c 0.231, DMF)
[00153] [00153] Chiral SFC (SFC-H method): Tr 3.14 min, MH + 597 100% chiral purity. Example 6: 4- (3 - ((1- (4-fluoro-2-methoxyphenyl) -2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5- acid synthesis methoxyphenoxy) butanoic (Compound 6) and chiral separation in Enantiomers 6A and 6B.
[00154] [00154] A mixture of 6- (trifluoromethoxy) indoline [CAS 959235-95-1] (2 g, 9.84 mmol), 2- (4-fluoro-2-methoxyphenyl) acetic acid [CAS 886498-61-9 ] (2.17 g, 10.8 mmol), HATU (5.62 g, 14.8 mmol) and diisopropylethylamine (4.9 mL, 29.5 mmol) in DMF (20 mL) was stirred at room for 3 h. Water and ice were added and the precipitate was filtered off and dried, yielding 2- (4-fluoro-2-methoxyphenyl) -1- (6- (trifluoromethoxy) indolin-1-yl) ethanone 6a (3.44 g). Synthesis of intermediate 6b:
[00155] [00155] At -78 ° C under a flow of N2, LiHMDS (18.7 mL, 18.7 mmol) was added dropwise to a mixture of 2- (4-fluoro-2-methoxyphenyl) - 1- ( 6- (trifluoromethoxy) indolin-1-yl) ethanone 6a (3.44 g, 9.32 mmol) in THF (45 mL). TMSCl (1.42 ml, 11.2 mmol) was added dropwise. The mixture was stirred for 15 min at -78 ° C and N-bromosuccinimide (1.83 g, 10.2 mmol) in THF (35 ml) was added dropwise. After stirring for 2 h at -78 ° C, the reaction was quenched with a saturated solution of NH4Cl. The mixture was extracted with EtOAc, dried over MgSO4, filtered and the solvent was concentrated under reduced pressure, giving 2-bromo-2- (4-fluoro-2-methoxyphenyl) -1- (6- (trifluoromethoxy) indolin- 1-yl) ethanone 6b (4.48 g). The crude compound was used without further purification in the next step. Synthesis of intermediate 6c:
[00156] [00156] A mixture of 2-bromo-2- (4-fluoro-2-methoxyphenyl) -1- (6- (trifluoromethoxy) indolin-1-yl) ethanone 6b (2.0 g, 4.46 mmol), Tert-Butyl 4- (3-amino-5-methoxyphenoxy) butanoate 1a (1.26 g, 4.46 mmol) and diisopropylethylamine (1.15 mL, 6.69 mmol) in CH3CN (45 mL) was stirred at 80 ° C for 5 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 µm, 40 g, heptane / EtOAc 85/15). Fractions containing expected compound were combined and the solvent was concentrated under reduced pressure, yielding 4- (3 - ((1- (4-fluoro-2-methoxyphenyl) - 2-oxo-2- (6- (trifluoromethoxy) terc-butyl indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoate 6c (1.6 g, 67% purity by LC / MS). Synthesis of Compound 6 and chiral separation in Enantiomers 6A and 6B:
[00157] [00157] A solution of 4- (3 - ((1- (4-fluoro-2-methoxyphenyl) -2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5- tert-butyl methoxyphenoxy) butanoate 6c (1.5 g, 2.31 mmol) in HCl (4 M in dioxane) (15 mL) was stirred at 5 ° C for 2 h and at room temperature for 3 h. The solvent was concentrated under reduced pressure and 3 N NaOH was added until neutral pH was obtained. The solution was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (20-45 µm, 40 g, CH2Cl2 / MeOH gradient from 99.5 / 0.5 to 95/5). The pure fractions were combined and the solvent was concentrated under reduced pressure, giving Compound 6 (646 mg). A small fraction was crystallized from CH3CN / diisopropyl ether, giving 4- (3 - ((1- (4-fluoro-2-methoxyphenyl) -2-oxo-2- (6- (trifluoromethoxy ) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoic (Compound 6, 35 mg). The remaining amount (600 mg) was used for chiral separation of the enantiomers via chiral SFC (Stationary phase: Chiralcel® OD-H 5 µm 250 x 20 mm, mobile phase: 60% CO2, 40% MeOH). To provide Enantiomer 6A as the first eluted product and Enantiomer 6B as the second eluted product. Both enantiomers were further purified by flash chromatography on silica gel (20-45 µm, 12 g, CH2Cl2 / MeOH gradient 100/0 to 95/5). The pure fractions were combined and the solvent was concentrated under reduced pressure, giving rise, after solidification in diisopropyl ether / pentane (+ a few drops of CH3CN), to Enantiomer 6A (108 mg) and Enantiomer 6B ( 108 mg), respectively. Compound 6: 1
[00158] [00158] H NMR (400 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.82 Hz, 2 H) 2.33 (t, J = 7.33 Hz, 2 H) 3.08 - 3.27 (m, 2 H) 3.61 (s, 3 H) 3.78 - 3.91 (m, 5 H) 3.92 - 4.02 (m, 1 H) 4.33 - 4 , 42 (m, 1 H) 5.59 (d, J = 8.59 Hz, 1 H) 5.75 (s, 1 H) 5.87 (dl, J = 7.07 Hz, 2 H) 6 , 39 (dl, J = 8.59 Hz, 1 H) 6.78 (td, J = 8.46, 2.27 Hz, 1 H) 6.94 - 7.02 (m, 2 H) 7, 29 - 7.35 (m, 2 H) 8.03 (s, 1 H) 12.14 (ls, 1 H)
[00159] [00159] LC / MS (LC-B method): Tr 2.76 min, MH + 593
[00160] [00160] Melting point: 164 ° C 6A enantiomer: 1
[00161] [00161] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.78 Hz, 2 H) 2.31 - 2.47 (m, 2 H) 3.10 - 3, 28 (m, 2 H) 3.62 (s, 3 H) 3.80 - 3.93 (m, 5 H) 3.93 - 4.06 (m, 1 H) 4.33 - 4.44 ( m, 1 H) 5.59 (dl, J = 8.51 Hz, 1 H) 5.76 (s, 1 H) 5.88 (dl, J = 8.83 Hz, 2 H) 6.39 ( dl, J = 8.83 Hz, 1 H) 6.79 (td, J = 8.43, 2.05 Hz, 1 H) 6.95 - 7.04 (m, 2 H) 7.30 - 7 , 37 (m, 2 H) 8.03 (s, 1 H) 12.16 (ls, 1 H)
[00162] [00162] LC / MS (LC-A method): Tr 2.86 min, MH + 593
[00163] [00163] [α] D20: -37.3 ° (c 0.255, DMF)
[00164] [00164] Chiral SFC (SFC-I method): Tr 1.03 min, MH + 593 100% chiral purity.
[00165] [00165] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.86 Hz, 2 H) 2.30 - 2.45 (m, 2 H) 3.09 - 3, 26 (m, 2 H) 3.62 (s, 3 H) 3.80 - 3.93 (m, 5 H) 3.93 - 4.06 (m, 1 H) 4.33 - 4.44 ( m, 1 H) 5.59 (dl, J = 8.51 Hz, 1 H) 5.76 (s, 1 H) 5.88 (dl, J = 8.83 Hz, 2 H) 6.39 ( dl, J = 8.51 Hz, 1 H) 6.79 (td, J = 8.43, 2.05 Hz, 1 H) 6.95 - 7.04 (m, 2 H) 7.30 - 7 , 37 (m, 2 H) 8.03 (ls, 1 H), 12.18 (ls, 1H)
[00166] [00166] LC / MS (LC-A method): Tr 2.88 min, MH + 593
[00167] [00167] [α] D20: + 32.7 ° (c 0.294, DMF)
[00168] [00168] Chiral SFC (SFC-I method): Tr 1.82 min, MH + 593 chiral purity 99.56%. Example 7: 4- (3 - ((1- (4-chlorophenyl) -1-deuterium-2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5- acid synthesis methoxyphenoxy) butanoic (Compound 7-D) and chiral separation in Enantiomers 7A-D and 7B-D Synthesis of intermediate 7a:
[00169] [00169] A mixture of 6- (trifluoromethoxy) indoline [CAS 959235-95-1] (2 g, 9.84 mmol), 2- (4-chlorophenyl) acetic acid [CAS 1878-66-6] (1, 85 g, 10.8 mmol), HATU (5.6 g, 14.8 mmol) and diisopropylethylamine (4.9 mL, 29.5 mmol) in DMF (40 mL) was stirred at room temperature for 12 h. Water was added and the precipitate was filtered off. The residue was taken up with EtOAc. The organic solution was washed with an aqueous 10% K2CO3 solution, brine, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 µm, 80 g, heptane / EtOAc gradient from 90/10 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2- (4-chlorophenyl) -1- (6- (trifluoromethoxy) indolin-1-yl) ethanone 7a (3 g). Synthesis of intermediate 7b:
[00170] [00170] At -78 ° C, under N2 flow, 1.5 M LiH-MDS in THF (11.2 mL, 16.9 mmol) was added dropwise to a mixture of 2- (4- chlorophenyl) -1- (6- (trifluoromethoxy) indolin-1-yl) ethanone 7a (3 g, 8.43 mmol) in THF (50 mL). The mixture was stirred for 15 min at -78 ° C and a solution of N-bromosuccinimide (1.65 g, 9.3 mmol) in THF (30 ml) was added dropwise. After stirring for 2 h at -78 ° C, the reaction was quenched with a saturated NH4Cl solution. The mixture was extracted with EtOAc. The organic layer was separated, dried with MgSO4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2- (4-chlorophenyl) -1- (6- (trifluoromethoxy) indolin-1-yl) ethanone 7b (3.6 g). The compound was used as such in the next step. Synthesis of intermediate 7c:
[00171] [00171] A mixture of 2-bromo-2- (4-chlorophenyl) -1- (6- (trifluoromethoxy) indolin-1-yl) ethanone 7b (3.6 g, 8.3 mmol), 4- Tert-butyl (3-amino-5-methoxy-phenoxy) -butanoate 1a (2.3 g, 8.3 mmol) and diisopropylethylamine (1.7 mL, 9.94 mmol) in CH3CN (80 ml) was stirred at 70 ° C for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1 N HCl and water. The organic phase was separated, dried over MgSO4, filtered, and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 µm, 120 g, heptane / EtOAc 80/20). The pure fractions were combined and evaporated to dryness, giving rise, after crystallization from diisopropyl ether, to 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- ( 6- tert-butyl 6- (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoate 7c (2.6 g). Synthesis of Compound 7 and chiral separation in Enantiomers 7A and 7B:
[00172] [00172] A solution of 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- (6- (trifluoro-methoxy) -indolin-1-yl) ethyl) amino) -5-methoxyphenoxy ) tert-butyl butanoate 7c (2.4 g, 3.8 mmol) in HCl (4 M in dioxane) (24 ml) was stirred at 5 ° C for 3 h and at room temperature for 3 h. The precipitate was filtered off and dried to give 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) amino acid) Methoxyphenoxy) butanoic as HCl salt (Compound 7, 2 g, 0.8 equiv. HCl, 0.07 equiv. H2O). Compound 7 (2 g, HCl salt) was neutralized before chiral separation by treating a solution of Compound 7 (HCl salt) with 1 N NaOH and evaporating the organic layer under reduced pressure. The enantiomers were separated via Chiral Preparative SFC (Stationary phase: Chiralcel® OD-H 5 µm 250 x 30 mm, mobile phase: 50% CO2, 50% iPrOH (+ iPrNH2 0.3%)) and further purified by of SFC Aquiral preparation (stationary phase: Cyano® 6 µm 150 x 21.2 mm, mobile phase: 80% CO2, 20% MeOH (+ iPrNH2 0.3%)). The product fractions were combined and evaporated under reduced pressure. The two enantiomers were collected with EtOAc and washed with 1 N HCl. The organic layers were separated, dried with MgSO4, filtered and the solvent was evaporated under reduced pressure. The first eluted enantiomer was solidified from ether / diisopropyl ether to give Enantiomer 7A (616 mg). The second eluted enantiomer was solidified from diisopropyl ether / ether to give Enantiomer 7B (715 mg). Compound 7: 1
[00173] [00173] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.9 Hz, 2 H) 2.34 (t, J = 7.3 Hz, 2 H) 3.07 - 3.28 (m, 2 H) 3.62 (s, 3 H) 3.85 (t, J = 6.5 Hz, 2 H) 4.04 (td, J = 10.5, 7.1 Hz, 1 H) 4.52 (td, J = 10.3, 6.5 Hz, 1 H) 5.57 (s, 1 H) 5.76 (t, J = 2.2 Hz, 1 H) 5.90 - 6.00 (m, 2 H) 7.01 (dd, J = 8.2, 1.6 Hz, 1 H) 7.33 (d, J = 8.2 Hz, 1 H) 7 , 41 - 7.48 (m, 2 H) 7.55 (d, J = 8.5 Hz, 2 H) 8.03 (s, 1 H)
[00174] [00174] LC / MS (LC-B method): Tr 2.70 min, MH + 579
[00175] [00175] Melting point: 150 ° C 7A enantiomer: 1
[00176] [00176] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.7 Hz, 2 H) 2.34 (tl, J = 7.3 Hz, 2 H) 3.08 - 3.27 (m, 2 H) 3.62 (s, 3 H) 3.85 (tl, J = 6.3 Hz, 2 H) 3.99 - 4.11 (m, 1 H) 4, 47 - 4.57 (m, 1 H) 5.57 (ls, 1 H) 5.76 (s, 1 H) 5.95 (dl, J = 10.1 Hz, 2 H) 6.45 (ls , 1 H) 7.01 (dl, J = 7.6 Hz, 1 H) 7.34 (dl, J = 7.9 Hz, 1 H) 7.44 (dl, J = 8.5 Hz, 2 H) 7.55 (dl, J = 8.2 Hz, 2 H) 8.04 (ls, 1 H) 12.12 (ls, 1 H)
[00177] [00177] LC / MS (LC-A method): Tr 2.95 min, MH + 579
[00178] [00178] [α] D20: -48.5 ° (c 0.27, DMF)
[00179] [00179] Chiral SFC (SFC-D method): Tr 1.13 min, MH + 579, chiral purity 100%. 7B Enantiomer: 1
[00180] [00180] H NMR (500 MHz, DMSO-d6) δ ppm 1.87 (tl, J = 6.8 Hz, 2 H) 2.34 (tl, J = 7.3 Hz, 2 H) 3.09 - 3.27 (m, 2 H) 3.62 (s, 3 H) 3.85 (tl, J = 6.1 Hz, 2 H) 3.99 - 4.10 (m, 1 H) 4, 46 - 4.59 (m, 1 H) 5.57 (s, 1 H) 5.76 (ls, 1 H) 5.95 (dl, J = 10.1 Hz, 2 H) 6.45 (ls , 1 H) 7.01 (dl, J = 7.9 Hz, 1 H) 7.34 (dl, J = 7.9 Hz, 1 H) 7.44 (dl, J = 8.2 Hz, 2 H) 7.55 (dl, J = 8.2 Hz, 2 H) 8.04 (ls, 1 H) 12.12 (ls, 1 H)
[00181] [00181] LC / MS (LC-A method): Tr 2.94 min, MH + 579
[00182] [00182] [α] D20: + 42.9 ° (c 0.28, DMF)
[00183] [00183] Chiral SFC (SFC-D method): Tr 2.13 min, MH + 579, chiral purity 100%. Synthesis of deuterated 7-D compound and chiral separation in Enantiomers 7A-D and 7B-D:
[00184] [00184] Copper (II) acetate (241 mg, 1.33 mmol) was added in one portion to a solution of Enantiomer 7A (384 mg, 0.663 mmol) in CH3CN (15 mL) at room temperature. The reaction mixture was heated in a sealed tube under microwave irradiation at 130 ° C for 2 h. The reaction mixture was evaporated to dryness under reduced pressure and the residue was taken up with CH2Cl2 and water. The layers were separated. The aqueous layer was extracted again with CH2Cl2. The combined organic layers were washed with brine and water, dried over MgSO4, filtered and evaporated under reduced pressure. The residue, containing impure intermediate 7d, was dissolved in MeOH (20 mL). Sodium cyanoborodeuteride (349 mg, 5.31 mmol) and two drops of acetic acid were added and the reaction mixture was stirred at room temperature for 55 h. More sodium cyborborodeuteride (48 mg, 0.663 mmol) and a few drops of acetic acid were added and the reaction mixture was stirred for 7 h at room temperature. The solvent was evaporated under reduced pressure. The residue was mixed with water and Et2O. The two-phase system was acidified to pH 1-2 by the addition of 1 N HCl. The layers were separated. The aqueous layer was extracted again with Et2O. The combined organic layers were dried over MgSO4 and the solvent was evaporated under reduced pressure. The residue was dried under vacuum at 50 ° C, yielding 4- (3 - ((1- (4-chlorophenyl) -1-deuterium-2-oxo-2- (6- (trifluoromethoxy) indoline- 1-yl) ethyl) amino) -5-methoxyphenoxy) racemic butane (Compound 7-D, 242 mg) as a white solid.
[00185] [00185] The enantiomers of Compound 7-D (242 mg) were separated via preparative SFC (Stationary phase: Kromasil (R, R) Whelk-O1 10/100, mobile phase: CO2, EtOH + iPrNH2 at 0.4 %). The product fractions were combined and evaporated under reduced pressure to provide Enantiomer 7A-D as the product eluted first and Enantiomer 7B-D as the product eluted second. Both enantiomers were mixed with Et2O and water. The mixture was acidified to pH 1-2 with 1N HCl. The layers were separated and the aqueous layer was extracted twice with Et2O. The combined organic layers were washed with water, dried over MgSO4, filtered, evaporated under reduced pressure and dried under vacuum at 50 ° C, giving Enantiomer 7A-D (85 mg, 92% deuterated according to 1H RMH) and Enantiomer 7B-D (77 mg, 92% deuterated according to 1H RMH) as almost white solids. Enantiomer 7A-D: 1
[00186] [00186] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 7.0 Hz, 2 H) 2.34 (t, J = 7.1 Hz, 2 H) 3.07 - 3.25 (m, 2 H) 3.61 (s, 3 H) 3.84 (t, J = 6.4 Hz, 2 H) 4.05 (td, J = 10.3, 7.1 Hz, 1 H) 4.52 (td, J = 10.3, 6.4 Hz, 1 H) 5.76 (t, J = 2.0 Hz, 1 H) 5.92 - 5.98 (m , 2 H) 6.45 (s, 1 H) 7.01 (dd, J = 8.1, 1.5 Hz, 1 H) 7.33 (d, J = 8.1 Hz, 1 H) 7 , 39 - 7.49 (m, 2 H) 7.51 - 7.60 (m, 2 H) 8.03 (s, 1 H) 12.17 (ls, 1 H)
[00187] [00187] LC / MS (LC-C method): Tr 1.13 min, MH + 580
[00188] [00188] [α] D20: + 54.2 ° (c 0.41, DMF)
[00189] [00189] Chiral SFC (SFC-E method): Tr 5.51 min, MH + 580, chiral purity 100%. 7B-D Enantiomer: 1
[00190] [00190] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 6.9 Hz, 2 H) 2.34 (t, J = 7.3 Hz, 2 H) 3.07 - 3.25 (m, 2 H) 3.61 (s, 3 H) 3.84 (t, J = 6.6 Hz, 2 H) 4.05 (td, J = 10.4, 7.3 Hz, 1 H) 4.52 (td, J = 10.3, 6.4 Hz, 1 H) 5.76 (t, J = 2.0 Hz, 1 H) 5.92 - 5.98 (m , 2 H) 6.45 (s, 1 H) 7.01 (dd,
[00191] [00191] LC / MS (LC-C method): Tr 1.10 min, MH + 580
[00192] [00192] [α] D20: -50.1 ° (c 0.459, DMF)
[00193] [00193] Chiral SFC (SFC-E method): Tr 6.10 min, MH + 580, chiral purity 100%. Example 8: 4- (3 - ((1- (4-chloro-2- (2-hydroxyethoxy) phenyl) -2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) acid synthesis amino) -5-methoxyphenoxy) butanoic (Compound 8).
[00194] [00194] To a mixture of 2- (4-chloro-2-hydroxyphenyl) ethyl acetate [CAS 1261826-30-5] (5.2 g, 24.2 mmol) and cesium carbonate (15.8 g, 48.5 mmol) in DMF (90 mL) at 10 ° C was added (2-bromo-
[00195] [00195] To a cooled (-70 ° C) solution of 1 M lithium bis (trimethylsilyl) amide in THF (41.8 mL, 41.8 mmol) was added a solution of 2- (2- (2- ( (tert-butyldimethylsilyl) oxy) -ethoxy) -4-chlorophenyl) ethyl acetate 8a (7.8 g, 20.9 mmol) in THF (45 mL). After stirring for 1 h at - 70 ° C, chlorotrimethylsilane (4.24 ml, 33.5 mmol) was added. The reaction mixture was stirred at -70 ° C for 15 min. N-Bromosuccinimide (4.46 g, 25.1 mmol) in THF (45 mL) was added and stirring was continued at -55 ° C for 2 h. The reaction mixture was poured into H2O and extracted twice with EtOAc. The organic layers were combined, dried over MgSO4, filtered and concentrated under reduced pressure, resulting in 2-bromo-2- (2- (2 - ((tert-butyldimethylsilyl) oxy) - ethoxy) -4-chlorophenyl) ethyl acetate 8b (10.1 g), which was used in the next step without further purification. Synthesis of intermediate 8c:
[00196] [00196] A mixture of 2-bromo-2- (2- (2 - ((tert-butyldimethylsilyl) oxy) ethoxy) -4-chlorophenyl) ethyl acetate 8b (2.0 g, 4.429 mmol), 4- ( Tert-Butyl 3-amino-5-methoxyphenoxy) butanoate 1a (1.62 g, 5.76 mmol) and diisopropylethylamine (1.53 mL, 8.86 mmol) in CH3CN (40 mL) was stirred at 50 ° C for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 µm, 80 g, heptane / EtOAc gradient 85/15 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure, yielding 4- (3 - ((1- (2- (2 - ((tert-butyldimethylsilyl) - oxy) ethoxy) -4-chlorophenyl) -2 -ethoxy-2-oxoethyl) amino) -5-methoxyphenoxy) tert-butyl butanoate 8c (1.1 g). Synthesis of intermediate 8d:
[00197] [00197] Lithium hydroxide monohydrate (142 mg, 3.37 mmol) in water (7.5 mL) was added dropwise to a solution of 4- (3 - ((1- (2- (2- tert-butyl terc-butyldimethylsilyl) oxy) -ethoxy) -4-chlorophenyl) -2-ethoxy-2-oxoethyl) amino) - 5-methoxyphenoxy) terc-butyl butanoate 8c (1.1 g, 1.69 mmol) CH3OH (1/1) (15 mL) at 10 ° C. The reaction was stirred at room temperature for 5 h, diluted with water and cooled to 0 ° C. The solution was slowly acidified to pH 6-7 with 0.5 N HCl and extracted with EtOAc. The organic layer was dried over MgSO4, filtered and the solvent was concentrated under reduced pressure, yielding 2 - ((3- (4- (tert-butoxy) -4-oxobutoxy) -5-methoxyphenyl) amino acid -2 - (2- (2 - ((tert-butyldimethylsilyl) oxy) ethoxy) -4-chlorophenyl) acetic 8d (675 mg). The compound was used without further purification in the next step. Synthesis of intermediate 8e:
[00198] [00198] To a solution of 2 - ((3- (4- (tert-butoxy) -4-oxobutoxy) - 5-methoxyphenyl) amino) -2- (2- (2 - ((tert-butyldimethylsilyl) oxide ) ethoxy) -4-chlorophenyl) acetic 8d (675 mg, 1.08 mmol) in DMF (6 mL) were added HATU (617 mg, 1.62 mmol), diisopropylethylamine (536 µL, 3.24 mmol) and 6- (trifluoromethoxy) indoline [CAS 959235-95-1] (220 mg, 1.08 mmol). The reaction mixture was stirred at room temperature for 7 days. The reaction mixture was diluted with water. The precipitate was removed by filtration, washed with water and collected with EtOAc. The organic layer was washed with a 10% K2CO3 solution and water, dried over MgSO4, filtered and the solvent was concentrated under reduced pressure, yielding 4- (3 - ((1- (2- (2- ( (tert-butyldimethylsilyl) oxy) ethoxy) -
[00199] [00199] Under a flow of N2 at 5 ° C, HCl (4 M in dioxane) (1.19 mL, 4.76 mmol) was added dropwise to a solution of 4- (3 - ((1- (2 - (2- ((tert-butyldimethylsilyl) oxy) -ethoxy) -4-chlorophenyl) -2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoate tert-butyl 8e (385 mg, 0.476 mmol) in MeOH (5 mL). The reaction was stirred at room temperature for 1 h. The mixture was cooled to 0 ° C, basified with a 10% aqueous solution of K2CO3 and extracted with EtOAc. The organic phase was separated, dried with MgSO4, filtered, and the solvent was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 µm, 24 g, CH2Cl2 / MeOH 99/1). The pure fractions were combined and the solvent was removed under reduced pressure, yielding 4- (3 - ((1- (4-chloro-2- (2-hydroxyethoxy) phenyl) -2-oxo-2- ( 6- methyl (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butaneate 8f (99 mg). Synthesis of Compound 8:
[00200] [00200] Lithium hydroxide monohydrate (32 mg, 0.76 mmol) in water (2.5 mL) was added dropwise to a solution of 4- (3 - ((1- (4- chlorine-2 - Methyl (2-hydroxyethoxy) phenyl) -2-oxo-2- (6- (trifluoromethoxy) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoate 8f (99 mg, 0.152 mmol) in THF ( 2.5 mL) at 10 ° C. The reaction was stirred at room temperature for 18 h and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (20-45 µm, 12 g, CH2Cl2 / MeOH gradient from 99/1 to 90/10). Fractions containing expected compound were combined and the solvent was removed under reduced pressure. A second purification was carried out via reverse phase HPLC (Stationary phase: YMC-actus Triart-C18 10 µm 30 x
[00201] [00201] H NMR (500 MHz, DMSO-d6) δ ppm 1.86 (quin, J = 6.86 Hz, 2 H) 2.28 - 2.47 (m, 2 H) 3.10 - 3, 27 (m, 2 H) 3.61 (s, 3 H) 3.68 - 3.88 (m, 4 H) 4.06 - 4.23 (m, 3 H) 4.39 (td, J = 10.09, 6.62 Hz, 1 H) 5.70 - 5.76 (m, 2 H) 5.91 (dl, J = 9.14 Hz, 2 H) 6.44 (d, J = 8 , 83 Hz, 1 H) 6.99 - 7.03 (m, 2 H) 7.12 (d, J = 1.89 Hz, 1 H) 7.34 (d, J = 8.20 Hz, 2 H) 8.02 (s, 1 H)
[00202] [00202] LC / MS (LC-B method): Tr 2.65 min, MH + 639 Example 9: 4- (3 - ((1- (4-chlorophenyl) -2- (5-methoxy-6) acid synthesis - (trifluoromethyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1-yl) -2-oxoethyl) amino) - 5-methoxyphenoxy) butanoic (Compound 9).
[00203] [00203] A suspension of 2-chloro-6-methyl-3- (trifluoromethyl) pyridine [CAS 1099597-74-6] (4.8 g, 24.6 mmol in sodium methoxide (25% in MeOH)) ( 24 mL, 105 mmol) was stirred at room temperature for 60 h. The mixture was poured into ice water and extracted twice with Et2O. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure, giving 2-methoxy-6-methyl-3- (trifluoromethyl) pyridine 9a (4.69 g). The product was used as such in the next step. Synthesis of intermediate 9b:
[00204] [00204] HNO3 (2.32 mL, 49.1 mmol) was added dropwise to a cooled (0 ° C) solution of 2-methoxy-6-methyl-3- (trifluoromethyl) pyridine 9a (4.69 g , 24.5 mmol) in H2SO4 (63.3 mL, 1.128 mol). The reaction mixture was stirred at 50 ° C for 60 h. The reaction mixture was poured carefully into ice water and the mixture was stirred at 0 ° C for 30 min. The solid was removed by filtration and washed with water, giving 2-methoxy-6-methyl-5-nitro-3- (trifluoromethyl) pyridine 9b (4.38 g) as a white solid. Synthesis of intermediate 9c:
[00205] [00205] 2-methoxy-6-methyl-5-nitro-3- (trifluoromethyl) pyridine 9b (4.38 g, 18.5 mmol) was dissolved in dry DMF (84 ml) under N2 atmosphere. DMF-DMA (12.2 ml, 91.5 mmol) was added and the reaction mixture was heated to 120 ° C for 4 h. After cooling to room temperature, the mixture was concentrated under reduced pressure and the solid residue was purified by column chromatography on silica gel (120 g) using a petroleum ether / EtOAc gradient from 100/0 to 60/40). The pure fractions were combined and the solvent was removed under reduced pressure, giving (E) -2- (6-methoxy-3-nitro-5- (trifluoromethyl) pyridin-2-yl) -N, N- dimethylethenamine 9c (4.5 g) as a red solid. Synthesis of intermediate 9d:
[00206] [00206] (E) -2- (6-methoxy-3-nitro-5- (trifluoromethyl) pyridin-2-yl) -N, N-dimethylethamine 9c (4.5 g, 15.5 mmol) was dissolved in toluene (87 ml) under N2 atmosphere. Silica gel (4.64 g), iron powder (8.63 g, 154.5 mmol) and acetic acid (35.4 ml) were added and the reaction mixture was stirred at 90 ° C for 2 h. The reaction mixture was filtered through Celite® and the solid was rinsed several times with EtOAc. The combined filtrates were evaporated and the residue was purified by column chromatography on silica gel (petroleum ether / EtOAc gradient 100/0 to 65/35), yielding 5-methoxy-6- (trifluoromethyl) -1H -pyrrole [3,2-b] pyridine 9d (3.1 g) as a yellow solid. Synthesis of intermediate 9e:
[00207] [00207] 5-Methoxy-6- (trifluoromethyl) -1H-pyrrolo [3,2-b] pyridine 9d (2.04 g, 9.44 mmol) was dissolved in dry CH2Cl2 (90 mL) under N2 atmosphere. DMAP (123 mg, 1.01 mmol) and Boc2O (2.49 g, 11.4 mmol) were added. The reaction mixture was stirred for 30 min at
[00208] [00208] 5-Methoxy-6- (trifluoromethyl) -1H-pyrrolo [3,2-b] tert-butyl pyridine-1-carboxylate 9e (1.45 g, 4.59 mmol) was dissolved in EtOH (30 mL) and the reaction was purged with nitrogen. Pd / C (10%) (976 mg, 0.917 mmol) was added to the reaction mixture, was hydrogenated overnight at 50 ° C. The reaction mixture was cooled to room temperature and filtered through Celite®. The filter cake was washed with EtOH and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / EtOAc gradient 100/0 to 95/5), giving 5-methoxy-6- (trifluoromethyl) -2,3-dihydro-1H-pyrrole [ 3,2-b] tert-butyl pyridine-1-carboxylate 9f (1.2 g) as a white solid. Synthesis of intermediate 9g:
[00209] [00209] A solution of tert-butyl 5-methoxy-6- (trifluoromethyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine-1-carboxylate (1.2 g, 3.77 mmol) in TFA / CH2Cl2 (1/1) (19 mL) was stirred at room temperature for 1 h. The reaction mixture was diluted with CH2Cl2 (60 ml), washed with a saturated aqueous solution of Na2CO3 (60 ml) and brine (60 ml). The organic layer was dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (40 g, petroleum ether / EtOAc gradient 80/20 to 40/60), yielding 5-methoxy-6- (trifluoromethyl) -2,3-di - hydro-1H-pyrrolo [3,2-b] pyridine 9g (745 mg) as a yellow solid. Synthesis of intermediate 9h:
[00210] [00210] 5-Methoxy-6- (trifluoromethyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridine
[00211] [00211] 2-Bromo-2- (4-chlorophenyl) -1- (5-methoxy-6- (trifluoromethyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridin-1- il) 9h ethanone (400 mg, 0.89 mmol) and tert-butyl 4- (3-amino-5-methoxyphenoxy) butanoate 1a (300 mg, 1.07 mmol) were dissolved in dry CH3CN (40 mL) under N2 atmosphere. Diisopropylethylamine (232 µL, 1.33 mmol) was added and the reaction mixture was heated to 70 ° C for 36 h. The reaction mixture was diluted with 20 ml of EtOAc and washed with 1 M HCl and brine. The organic layer was dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (40 g, toluene / EtOAc gradient 100/0 to 94/6). A second purification was performed by column chromatography on silica gel (2x12 g, petroleum ether / acetone gradient 100/0 to
[00212] [00212] 4- (3 - ((1- (4-Chlorophenyl) -2- (5-methoxy-6- (trifluoromethyl) -2,3-dihydro-1H-pyrrolo [3,2-b] pyridin -1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy) tert-butylbutanoate 9i (341 mg, 0.525 mmol) was dissolved under the atmosphere of N2 in HCl (4 M in dioxane) (6 , 62 ml). The reaction was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (40 g, toluene / EtOAc / AcOH gradient 99/0/1 to 50/49/1). A second purification was carried out on silica gel (2x12 g, CH2Cl2 / MeOH / AcOH gradient 99/0/1 to 96/3/1). A third purification was carried out on silica gel (12 g, CH2Cl2 / MeOH / AcOH gradient 98/1/1 to 96.5 / 2.5 / 1). The pure fractions were combined and concentrated under reduced pressure, yielding 4- (3 - ((1- (4-chlorophenyl) -2- (5-methoxy-6- (trifluoromethyl) -2,3-di -hydro-1H-pyrrolo [3,2- b] pyridin-1-yl) -2-oxoethyl) amino) -5-methoxyphenoxy) butanoic (compound 9, 72 mg) as a white solid. Compound 9: 1
[00213] [00213] H NMR (500 MHz, DMSO-d6) δ ppm 1.84 - 1.91 (m, 2 H) 2.30 - 2.37 (m, 2 H) 3.21 - 3.30 (m , 2 H) 3.62 (s, 3 H) 3.80 - 3.89 (m, 2 H) 3.94 (s, 3 H) 3.98 - 4.12 (m, 1 H) 4, 56 (td, J = 10.64, 6.15 Hz, 1 H) 5.58 (d, J = 8.83 Hz, 1 H) 5.76 (t, J = 1.89 Hz, 1 H) 5.95 (dl, J = 10.72 Hz, 2 H) 6.40 (d, J = 8.83 Hz, 1 H) 7.44 (d, J = 8.51 Hz, 2 H) 7, 56 (d, J = 8.51 Hz, 2 H) 8.53 (s, 1 H) 12.06 - 12.26 (m, 1 H)
[00214] [00214] LC / MS (LC-A method): Tr 2.87 min, MH + 594 Example 10: 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- (2 - (triple
[00215] [00215] A solution of 2- (3-amino-5- (trifluoromethyl) thiophen-2-yl) ethyl acetate ([CAS 860398-39-6] (1.49 g, 5.88 mmol) in CH3CN (40 mL) was stirred at room temperature under an atmosphere of N2. NaHCO3 (0.544 g, 6.47 mmol) and 2- (4-chlorophenyl) acetyl chloride ([CAS 25026- 34-0] (861 µL, 5 , 88 mmol) were added and the reaction mixture was stirred at room temperature for 100 min. The mixture was poured into H2O with stirring (200 ml) and extracted with Et2O (2x 100 ml). The combined organic layers were washed with aqueous solution saturated sodium chloride, dried over MgSO4, filtered and evaporated under reduced pressure.The residue was purified by flash chromatography on silica gel (50 g) using a 100/0 to 80/20 heptane / EtOAc gradient. The desired compounds were combined, evaporated under reduced pressure and coevaporated with toluene, yielding ethyl 2- (3- (2- (4-chlorophenyl) acetamido) -5- (trifluoromethyl) thiophen-2-yl) acetate 10a (1, 15 g).
[00216] [00216] A solution of 2 M LiBH4 in THF (2.59 mL, 5.18 mmol) was added slowly to a solution with stirring of 2- (3- (2- (4-chlorophenyl) acetamido) -5- ( trifluoromethyl) thiophen-2-yl) ethyl acetate 10a (1.05 g, 2.59 mmol) in 2-Me-THF (20 mL). The reaction mixture was stirred at room temperature for 18h. The mixture was poured into a mixture with stirring H2O (100 ml) and Et2O (100 ml). 1N HCl (10 mL) was added dropwise (foaming) and, after stirring for 15 minutes, the layers were separated. The organic layer was washed with saturated sodium chloride solution, dried over MgSO4, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (25 g) using a gradient of heptane / iPrOH 100/0 to 50/50. The desired fractions were combined, evaporated under reduced pressure and coevaporated with toluene. The residue was stirred in toluene (6 ml) at 45 ° C for 15 minutes, removed by filtration at room temperature, washed with toluene (3x) and dried under vacuum at 50 ° C, giving 2- (4-chlorophenyl) - N- (2- (2-hydroxyethyl) -5- (trifluoromethyl) thiophen-3-yl) acetamide 10b (1.15 g). Synthesis of intermediate 10c:
[00217] [00217] Triphenylphosphine (1.02 g, 3.85 mmol) was added to a stirred solution of 2- (4-chlorophenyl) -N- (2- (2-hydroxyethyl) -5- (trifluoro-methyl ) thiophen-3-yl) acetamide 10b (1.0 g, 2.75 mmol) in THF (20 mL) under N2 atmosphere. Di-tert-butyl azodicarboxylate (0.71 g, 3.02 mmol) was added and the resulting solution was stirred at room temperature for 20 h. The volatiles were evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (25 g) using a gradient of CH2Cl2 / heptane 0/100 to 100/0. The desired fractions were combined and concentrated under reduced pressure to a residual volume of 15 mL. The product was allowed to crystallize over a period of 4 days. The solids were removed by filtration, washed with heptane (4x) and dried under vacuum at 50 ° C, giving 2- (4-chlorophenyl) -1- (2- (trifluoromethyl) -5,6-dihydro- 4H-tie-no [3,2-b] pyrrol-4-yl) ethanone 10c (0.75 g). Synthesis of intermediate 10d:
[00218] [00218] At -75 ° C, under a flow of N2, 1 M LiHMDS in THF (4.34 mL, 4.34 mmol) was added dropwise to a mixture of 2- (4-chlorophenyl) -1- (2- (trifluoromethyl) -5,6-dihydro-4H-thieno [3,2-b] pyrrol-4-yl) ethanone 10c (750 mg, 2.17 mmol) in 2-Me-THF (30 ml) and the mixture was kept at -75 ° C for 20 min. TMSCl (444 µL, 3.47 mmol) was added dropwise. The mixture was stirred for 20 min at -75 ° C and a solution of N-bromosuccinimide (502 mg, 2.82 mmol) in THF (5 ml) was added dropwise. After stirring for 20 min at -75 ° C, the reaction was quenched with a saturated aqueous solution of NH4Cl (25 ml). The cooling bath was removed and the reaction mixture was stirred until the reaction temperature reached -15 ° C. Water (25 ml) and DIPE (25 ml) were added and the mixture was stirred for 10 min. The organic layer was separated and the aqueous phase was extracted with Et2O. The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure, giving 2-bromo-2- (4-chlorophenyl) -1- (2- (trifluoromethyl) -5,6-dihydro -4H-thieno [3,2- b] pyrrol-4-yl) ethanone 10d (921 mg), which was used as such in the next step. Synthesis of intermediate 10e:
[00219] [00219] A mixture of 2-bromo-2- (4-chlorophenyl) -1- (2- (trifluoromethyl) -5,6-dihydro-4H-thieno [3,2-b] pyrrole-4 -yl) ethanone 10d (921 mg, 2.17 mmol), tert-butyl 4- (3-amino-5-methoxyphenoxy) butanoate 1a (1.22 g, 4.34 mmol) and diisopropylethylamine (747 µL , 4.34 mmol) in 2-butanol (15 mL) was stirred at 45 ° C for 2 h. The reaction mixture was allowed to reach room temperature and poured into water with stirring (50 ml). The product was extracted (2x) with Et2O. The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure and coevaporated with dioxane (2x). The residue was purified by flash chromatography on silica gel (40 g) using a gradient of heptane / EtOAc / EtOH 100/0/0 to 40/45/15. The desired fractions were combined, evaporated under reduced pressure and co-evaporated with dioxane (2x), yielding 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- (2- (trifluoromethyl) -5,6-dihydro-4H-thieno [3,2-b] pyrrol-4-yl) ethyl) amine) -5-methoxyphenoxy) tert-butyl 10ano butanoate (1.36 g), which was used as such in the next step. Synthesis of Compound 10 and chiral separation in Enantiomers 10A and 10B:
[00220] [00220] 4- (3 - ((1- (4-Chlorophenyl) -2-oxo-2- (2- (trifluoromethyl) -5,6-dihydro-4H-thieno [3,2-b] pyrrole -4-yl) ethyl) amino) -5-methoxyphenoxy) tert-butyl 10e butanoate (1.36 g, 2.17 mmol) was mixed with 4 M HCl in dioxane (15 mL) and the mixture was stirred at temperature room for 20 h. The solids were removed by filtration, washed with dioxane (3x) and dried under vacuum at 50 ° C. The residue (1.4 g) was purified via preparative HPLC (Stationary phase: RP XBridge® Prep C18 OBD - 10 µm, 50 x 150 mm, mobile phase: 0.25% NH4HCO3 solution in water, CH3CN). The desired fractions were combined and the volatile organics were evaporated under reduced pressure. The remaining aqueous solution was extracted (2x) with a solvent mixture of Et2O / 2- Me-THF (2/1). The combined organic layers were washed with brine, dried over MgSO4, filtered and evaporated under reduced pressure, giving 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- (2- crude (trifluoromethyl) -5,6-dihydro-4H-thieno [3,2-b] pyrrol-4-yl) ethyl) amino) -5-methoxyphenoxy) (Compound 10, 0.54 g). An analytical sample (40 mg) was dissolved in Et2O with stirring (1 mL) and 4 M HCl in dioxane (250 µL) was added. After stirring for 2 min, the product was removed by filtration, washed (3x) with Et2O / dioxane (4/1) and dried under vacuum at 50 ° C, giving Compound 10 (20 mg).
[00221] [00221] Compound 10 enantiomers (500 mg) were separated by preparative chiral SFC (Stationary phase: Chiralpak® Diacel IC 20 x 250 mm, mobile phase: CO2, EtOH). The product fractions of the first eluted enantiomer were combined, evaporated under reduced pressure and purified by flash chromatography on silica gel (12 g) using a gradient of heptane / EtOAc: EtOH: AcOH 100/0: 0: 0 to 60/30 : 9.8: 0.2. The desired fractions were combined, evaporated under reduced pressure and coevaporated with DCM. The residue was dried in vacuo at 50 ° C, yielding Enantiomer 10A (164 mg). The product fractions of the second eluted enantiomer were combined, evaporated under reduced pressure and purified by flash chromatography on silica gel (12 g) using a gradient of heptane / EtO-Ac: EtOH: AcOH 100/0: 0: 0 to 60/30: 9.8: 0.2. The desired fractions were combined, evaporated under reduced pressure and coevaporated with DCM. The residue was dried under vacuum at 50 ° C, giving rise to Enantiomer 10B (167 mg). Compound 10: 1
[00222] [00222] H NMR (360 MHz, DMSO-d) δ ppm 1.87 (t, J = 6.8 Hz, 2 H), 2.31 - 2.37 (m, 2 H), 3.26 - 3.38 (m, 2 H), 3.62 (s, 3 H), 3.84 (tl, J = 6.4 Hz, 2 H), 4.29 (td, J = 10.5, 6 , 8 Hz, 1 H), 4.79 (td, J = 10.2, 6.2 Hz, 1 H), 5.49 (s, 1 H), 5.76 (t, J = 2.0 Hz, 1 H), 5.91 - 5.97 (m, 2 H), 7.44 (d, J = 8.4 Hz, 2 H), 7.54 (d, J = 8.8 Hz, 2 H), 7.76 (s, 1 H)
[00223] [00223] LC / MS (LC-D method): Tr 1.93 min, MH + 569 10A enantiomer: 1
[00224] [00224] H NMR (400 MHz, DMSO-d6) δ ppm 1.83 - 1.91 (m, 2 H), 2.30 - 2.36 (m, 2 H), 3.23 - 3.30 (m, 2 H), 3.62 (ls, 3 H), 3.85 (ls, 2 H), 4.30 (m, J = 9.5 Hz, 1 H), 4.79 (m, J = 6.8 Hz, 1 H), 5.48 (dl, J = 8.8 Hz, 1 H), 5.76 (ls, 1 H), 5.94 (dl, J = 9.0 Hz , 2 H), 6.35 (dl, J = 8.1 Hz, 1 H), 7.43 (dl, J = 7.3 Hz, 2 H), 7.54 (dl, J = 8.1 Hz, 2 H), 7.76 (ls, 1 H), 12.10
[00225] [00225] LC / MS (LC-C method): Tr 1.03 min, MH + 569
[00226] [00226] [α] D20: + 36.9 ° (c 0.4445, DMF)
[00227] [00227] Chiral SFC (SFC-F method): Tr 5.52 min, MH + 569 chiral purity 100%. 10B Enantiomer: 1
[00228] [00228] H NMR (400 MHz, DMSO-d6) δ ppm 1.83 - 1.91 (m, 2 H), 2.34 (tl, J = 6.8 Hz, 2 H), 3.23 - 3.30 (m, 2 H), 3.62 (s, 3 H), 3.85 (tl, J = 5.9 Hz, 2 H), 4.25 - 4.35 (m, 1 H) , 4.75 - 4.83 (m, 1 H), 5.48 (dl, J = 8.4 Hz, 1 H), 5.76 (ls, 1 H), 5.94 (dl, J = 8.8 Hz, 2 H), 6.35 (dl, J = 8.4 Hz, 1 H), 7.43 (dl, J = 7.7 Hz, 2 H), 7.54 (dl, J = 7.9 Hz, 2 H), 7.76 (s, 1 H), 12.11 (ls, 1 H)
[00229] [00229] LC / MS (LC-C method): Tr 1.03 min, MH + 569
[00230] [00230] [α] D20: -39.1 ° (c 0.437, DMF)
[00231] [00231] Chiral SFC (SFC-F method): Tr 6.98 min, MH + 569 chiral purity 97%. Example 11: 4- (3 - ((1- (4-chlorophenyl) -2-oxo-2- (6- ((trifluoromethyl) thio) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy acid synthesis ) butanoic (Compound 11)
[00232] [00232] To the suspension of NaH (26.5 g, 663 mmol, 60% in oil) in THF (100 mL) at 0 ° C was added 6-bromo-1H-indole [CAS 52415-29-9] (100 g, 510 mmol) in portions. The reaction was stirred for 30 min at 15 ° C. After cooling to 0 ° C, SEMCl (93.6 g, 561 mmol, 99.5 ml) was added. The reaction mixture was stirred for 16 h at 15 ° C and poured into a saturated aqueous solution of ammonium chloride (200 ml). The mixture was diluted with ethyl acetate (300 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate (2x 200 ml). The combined organic layers were washed with brine (500 ml), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel using petroleum ether. The product fractions were combined and evaporated under reduced pressure to give 6-bromo-1 - ((2- (trimethylsilyl) ethoxy) methyl) -1H-indole 11a (134 g) as a yellow oil. Synthesis of intermediate 11b:
[00233] [00233] A mixture of 6-bromo-1 - ((2- (trimethylsilyl) ethoxy) methyl) -1H-indole 11a (134 g, 411 mmol), 4.4.4 ', 4', 5.5, 5 ', 5'-octamethyl-2,2'-bi (1,3,2-
[00234] [00234] To a solution of 6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1 - ((2- (trimethylsilyl) ethoxy) methyl) -1H-indole 11b (52 g, 139 mmol) in acetone (2.4 L) and H2O (2.4 L) were added NaIO4 (119 g, 557 mmol) and NH4OAc (53.7 g, 696 mmol). The reaction mixture was stirred at 25 ° C for 16 hours. The reaction was duplicated on the same scale (52 g of compound 11b) and the reaction mixtures of both reactions were combined for manipulation. The precipitate was removed by filtration and the solvent (acetone) was removed under reduced pressure. Ethyl acetate (5 L) was added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3x 5 L). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give boronic acid (1 - ((2- (trimethylsilyl) ethoxy) methyl) - 1H-indol-6-yl) 11c (85 g) as a very dark brown solid that was used in the next step without further purification. Synthesis of intermediate 11d:
[00235] [00235] A mixture of TMSCF3 (207.5 g, 1.46 mol), CuSCN (10.7 g, 87.6 mmol), S8 (224.6 g, 875.6 mmol), acid (1- ( (2- (trimethylsilyl) ethoxy) methyl) -1H-indol-6-yl) boronic 11c (85 g, 292 mmol), Ag2CO3 (161 g, 584 mmol), K3PO4 (186 g, 876 mmol), 1 , 10-phenanthroline (31.6 g, 175 mmol) and 4 Å molecular sieves (85 g) in DMF (1 L) was stirred at 25 ° C for 16 hours under N2 atmosphere. The reaction mixture was filtered on a Celite® pad. The filtrate was diluted with MTBE (1 L), washed with water (3x 500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate 100/1). The product fractions were combined and evaporated under reduced pressure to give 6 - ((trifluoromethyl) thio) -1 - ((2- (trimethylsilyl) ethoxy) methyl) - 1H-indole 11d (38 g) as a yellow oil clear. Synthesis of intermediate 11e:
[00236] [00236] To the solution of 6 - ((trifluoromethyl) thio) -1 - ((2- (trimethylsilyl) ethoxy) methyl) -1H-indole 11d (38 g, 109 mmol) in THF (1.5 L) was added - of TBAF.3H2O (345 g, 1.09 mol) and ethane-1,2-diamine (131.45 g, 2.19 mol). The reaction mixture was stirred at 70 ° C for 16 h. The reaction mixture was cooled to 25 ° C and poured into saturated aqueous NaHCO3 (3 L). The aqueous mixture was extracted with ethyl acetate (3x 1 L). The combined organic layers were dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Gemini C18 250 x 50 mm 10 µm, mobile phase: water (0.05% v / v ammonium hydroxide), CH3CN), giving rise to 6 - ((trifluoromethyl) ) thio) -1H-indole 11e (10.1 g) as an off-white solid. Synthesis of intermediate 11f:
[00237] [00237] A mixture of 6 - ((trifluoromethyl) thio) -1H-indole 11e (1.0 g, 4.6 mmol) and borane dimethyl sulfide complex (7 mL) was heated in a sealed tube at 75 ° C for 5 h. The reaction mixture was allowed to reach room temperature and added dropwise to MeOH with stirring (30 ml) (exotherm). After the addition, the resulting solution was heated to reflux for 3 h. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (25 g) using a 100/0 to 40/60 heptane / CH2Cl2 gradient. The desired fractions were combined, evaporated under reduced pressure and coevaporated with dioxane. The product was dried under vacuum at 50 ° C, yielding 6 - ((trifluoromethyl) thio) indoline 11f (0.79 g). Synthesis of intermediate 11g:
[00238] [00238] A solution of 6 - ((trifluoromethyl) thio) indoline 11f (0.79 g, 3.6 mmol) in CH3CN (30 mL) was stirred under an N2 atmosphere. NaHCO3 (0.333 g, 3.96 mmol) was added and the reaction mixture was cooled in an ice bath. A solution of 2- (4-chlorophenyl) acetyl chloride ([CAS 25026-34-0] (0.852 g, 4.51 mmol) in CH3CN (20 mL) was added and the reaction mixture was stirred at room temperature for 16 h) The mixture was poured into H2O with stirring (100 mL). The precipitate was removed by filtration and washed with water (4x 10 mL). The solids were stirred in Et2O / heptane (3/2) (20 mL), removed by filtration, washed with Et2O / heptane (3/2) (2x 10 mL) and dried under vacuum at 50 ° C, giving 2- (4-chlorophenyl) -1- (6 - ((trifluoromethyl) thio) ) indolin-1-yl) ethanone 11g (1.033 g). Synthesis of intermediate 11h:
[00239] [00239] At -78 ° C, under a flow of N2, 1 M LiHMDS in THF (5.56 mL, 5.56 mmol) was added dropwise to a mixture of 2- (4-chlorophenyl) -1- (6 - ((trifluoromethyl) thio) indolin-1-yl) ethanone 11g (1.033 mg, 2.78 mmol) in 2-Me-THF (40 mL) and the mixture was maintained at -78 ° C for 20 min. TMSCl (568 µL, 4.45 mmol) was added dropwise. The mixture was stirred for 35 min at -78 ° C and a solution of N-bromosuccinimide (643 mg, 3.61 mmol) in THF (8 ml) was added dropwise. After stirring for 35 min at -78 ° C, the reaction was quenched with a saturated aqueous solution of NH4Cl (30 ml). The cooling bath was removed and the reaction mixture was stirred until the reaction reached room temperature. Water (30 ml) and DIPE (30 ml) were added and the mixture was stirred for 20 min. The organic layer was separated, washed with brine, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure, giving 2-bromo-2- (4-chlorophenyl) -1- (6 - ((trifluoromethyl) thio) indolin-1-yl) ethanone 11h (1.25 g), which was used as such in the next step. Synthesis of intermediate 11i:
[00240] [00240] A mixture of 2-bromo-2- (4-chlorophenyl) -1- (6 - ((trifluoromethyl) thio) indolin-1-yl) ethanone 11h (1.25 mg, 2.78 mmol), 4 - tert-Butyl (3-amino-5-methoxyphenoxy) butanoate 1a (1.56 g, 5.56 mmol) and diisopropylethylamine (957 µL, 5.56 mmol) in 2-butanol (25 mL) was stirred - at 45 ° C for 16 h. The reaction mixture was allowed to reach room temperature and poured into water with stirring (100 ml). The product was extracted (2 x) with CH2Cl2. The combined organic layers were washed with brine, dried over MgSO4, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (40 g) using a gradient of heptane / EtOAc / EtOH 100/0/0 to 70/20/10. The desired fractions were combined and evaporated under reduced pressure, giving 4- (3- ((1- (4-chlorophenyl) -2-oxo-2- (6 - ((trifluoromethyl) thio) indolin-1-yl) tert-butyl ethyl) amino) -5-methoxyphenoxy) butanoate 11i (2.0 g), which was used as such in the next step. Synthesis of Compound 11:
[00241] [00241] 4- (3 - ((1- (4-Chlorophenyl) -2-oxo-2- (6 - ((trifluoromethyl) thio) indolin-1-yl) ethyl) amino) -5-methoxyphenoxy) butanoate tert-butyl 11i (1.81 g, 2.78 mmol) was mixed with 4 M HCl in dioxane (20 mL) and the mixture was stirred at room temperature for 3.5 h. The solids were removed by filtration, washed with dioxane (3x) and Et2O (20 ml). The solid was dissolved in CH2Cl2 (100 ml) and mixed with water (50 ml) and saturated aqueous Na2CO3 (30 ml). After stirring for 15 min, the layers were separated. The organic layer was washed with brine.
[00242] [00242] H NMR (360 MHz, DMSO-d6) δ ppm 1.87 (quin, J = 7.1 Hz, 2 H) 2.25 - 2.38 (m, 2 H) 3.16 - 3, 27 (m, 2 H) 3.62 (s, 3 H) 3.81 - 3.87 (m, 2 H) 3.95 - 4.08 (m, 1 H) 4.44 - 4.56 ( m, 1 H) 5.57 (dl, J = 8.8 Hz, 1 H) 5.74 - 5.77 (m, 1 H) 5.90 - 5.98 (m, 2 H) 6.47 (dl, J = 8.8 Hz, 1 H) 7.34 - 7.40 (m, 2 H) 7.41 - 7.48 (m, 2 H) 7.51 - 7.59 (m, 2 H) 8.39 (s, 1 H) 12.16 (ls, 1 H)
[00243] [00243] LC / MS (LC-C method): Tr 1.12 min, MH + 595 Table: compounds prepared as described above Compound Structure Optical rotation Cl OMe
[00244] [00244] The antiviral activity of all compounds of the invention was tested against the 16681 DENV-2 strain that was labeled with enhanced green fluorescent protein (eGFP). The culture medium consists of a minimum essential medium supplemented with 2% fetal calf serum inactivated by heat, 0.04% gentamicin (50 mg / mL) and 2 mM L-glutamine. Vero cells, obtained from ECACC, were suspended in culture medium and 25 µL were added to 384-well plates (2500 cells / well), which already contain the antiviral compounds.
[00245] [00245] In parallel, the toxicity of the compounds was evaluated on the same plates. As soon as the eGFP signal was read, 40 µL of ATPlite, a cell viability dye, was added to all wells of the 384-well plates. ATP is present in all metabolically active cells and the concentration decreases very rapidly when the cells undergo necrosis or apoptosis. The ATPLite assay system is based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin. The plates were incubated for 10 minutes at room temperature. Then, the plates were measured in a ViewLux. The semi-maximum cytotoxic concentration (CC50) was also determined, defined as the concentration required to reduce the luminescent signal by 50% compared to that of the cell control wells. Finally, the selectivity index (SI) was determined for the compounds, which was calculated as follows: SI = CC50 / EC50.
[00246] [00246] The antiviral activity of the compounds of the invention has been tested against the DENV-1 TC974 # 666 (NCPV) strain, DENV-2 16681 strain, DENV-3 H87 (NCPV) strain and DENV-4 H241 strain ( NCPV) in an RT-qPCR assay. Therefore, Vero cells were infected with DENV-1 or -2 or -3 or -4 in the presence or absence of test compounds. On day 3 post-infection, cells were lysed and cell lysates were used to prepare cDNA from both a viral target (at 3'UTR of DENV; Table 2) and a cell reference gene (β-actin, Table 2 ). Subsequently, a real-time duplex PCR was performed on a Lightcycler480 instrument. The generated Cp value is inversely proportional to the amount of RNA expression of these targets. Inhibition of DENV replication by a test compound results in a shift of Cps to the 3´UTR gene. On the other hand, if a test compound is toxic to cells, a similar effect on the expression of β-actin will be observed. The ΔΔCp comparative method is used to calculate the EC50, which is based on the relative genetic expression of the target gene (3'UTR) normalized with the cell maintenance gene (β-actin). In addition, CC50 values are determined based on the Cp values acquired for the β-actin maintenance gene. Table 2: Primers and probes used for quantitative RT-PCR, in real time. Sequencing Target Primer / Probe, b F3utr258 DENV 5'-CGGTTAGAGGAGACCCCTC-3 'R3utr425 DENV 5'-GAGACAGCAGGATCTCTGGTC-3' P3utr343 3'-UTR by DENV FAM-5'R3utr425 - AGGTTAGAGGAGACCCCCC-3'-IABkFQ Factina743 β-actin 5'-GGCCAGGTCATCACCATT-3 'Ractina876 β-actin 5'-ATGTCCACGTCACACTTCATG-3' Pactina773 β-actin HEX-5'-TTCCGCT-5'-TTCCGCT-5'-TTCC Reporter dyes (FAM, HEX) and extinguishing elements (ZEN and IABkFQ) are indicated in bold and italics. b The nucleotide sequence of the primers and probes was selected from the region conserved in the 3´UTR region of the dengue virus genome, based on the alignment of 300 nucleotide sequences of the four dengue serotypes deposited at Genbank (Gong et al., 2013, Methods Mol Biol, Chapter 16).
[00247] [00247] The culture medium consisted of a minimum essential medium supplemented with 2% fetal calf serum inactivated by heat, 0.04% genotamycin (50 mg / mL) and 2 mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in culture medium and 75 µL / well were added to 96-well plates (10,000 cells / well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 steps of dilution of the test compound to 200 times the final concentration in 100% DMSO (500 nL; final concentration range: 25 µM - 0.000064 µM or 2 , 5 µM -
[00248] [00248] In the preparation of the reverse transcription step, mixture A (table 3A) was prepared and 7.57 µL / well were distributed in a 96-well plate. After adding 5 µL of the cell lysates, a five minute denaturation step was performed at 75 ° C (table 3B). Then, 7.43 µL of mixture B was added (table 3C) and the reverse transcription step was started (table 3D) to generate cDNA.
[00249] [00249] Finally, a mixture of RT-qPCR was prepared, mixture C (table 4A), and 22.02 µL / well were distributed in 96-well LightCycler qPCR plates to which 3 µL of cDNA were added. and qPCR was performed according to the conditions in table 4B on a LightCycler 480.
[00250] [00250] Using the LightCycler software and an internal LIMS system, dose response curves for each compound were calculated and the effective semi-maximum concentration (EC50) and the semi-maximum cytotoxic concentration (CC50) were determined (Tables 5-8). Table 3: Synthesis of cDNA using Mixture A, denaturation, Mixture B and reverse transcription. Mixture AA Plates 8 Samples 828 Reaction Vol. (ΜL) 20 Mixing Item Concentration Volume for (µL) Unit Final Stock 1 sample x H2O samples Milli-Q 7.27 6019.56 R3utr425 µM 20 0.27 0.15 124 , 20 Ractin876 µM 20 0.27 0.15 124.20 Mix volume / well (µL) 7.57 Cell lysates 5.00 B Denaturation stage: Temp stage Time Denaturation 75 ° C 5 'Maintenance 4 ° C maintenance C Mixture B Samples 864 Mixing Item Concentration Volume for (µL) Unit Final Stock 1 sample x buffer samples Expand HIFI 2 X 10.00 1.00 2.00 1728.0 MgCl2 mM 25.00 3.50 2.80 2419, 2 mM dNTPs 10.00 1.00 2.00 1728.0 Rnase Inhibitor U / µL 40.00 1.00 0.50 432.0 Expand RT U / µL 50.00 0.33 0.13 112.3 Total Volume Mixture (µL) 7.43 D cDNA synthesis protocol Stage Temp Time Transc rev 42 ° C 30 'Denaturation 99 ° C 5' Maintenance 4 ° C maintenance
Table 4: Mixture and qPCR protocol.
Reaction Vol. Samples 833 25 (µL) Mixing Item Concentration Volume to (µL) Final Stock Unit 1 sample x Roche PCR grade H2O samples 7.74 6447.42 2xMM Roche X 2 1 12.50 10412.50 F3utr258 µM mix 20 0.3 0.38 316.54 R3utr425 µM 20 0.3 0.38 316.54 P3utr343 µM 20 0.1 0.13 108.29 Factina743 µM 20 0.3 0.38 316.54 Ractin876 µM 20 0 , 3 0.38 316.54 Pactin773 µM 20 0.1 0.13 108.29 Volume Mix / Tube (µL) 22.02 cDNA 3.00
B qPCR3 Protocol Rate of Step Temp Time ramp pre-incub / skim 95 ° C 10 min 4.4 Denaturation 95 ° C 10 sec 4.4 annealing 58 ° C 1 min 2.2 40 cycles Elongation 72 ° C 1 sec 4, 4 Cooling 40 ° C 10 sec 1.5
Table 5: EC50, CC50 and SI for compounds against serotype 1 in RT-qPCR assays RT-qPCR serotype 1 TC974 # 666 Compound No. EC50 (µM) N CC50 (µM) N SI N 1B 0.000096 4 > 2.5 4> 79500 4 2B 0.000091 5> 1.0 5> 33 100 5 3B 0.00010 3> 2.5 3> 54200 3 4B 0.00011 4> 1.0 4> 45200 4 5B 0, 00033 3> 1.0 3> 5910 3 6B 0.00064 4 13 4 20 500 4 7A-D 0.00024 3> 1.0 3> 6180 3 10A 0.00022 5 13 5 56000 5 N = the number of independent experiments in which the compounds were tested.
Table 6: EC50, CC50 and SI for compounds against serotype 2 in RT-qPCR assays RT-qPCR serotype 2 16681 No. of compound EC50 (µM) N CC50 (µM) N SI N 1B 0.00018 4> 2 , 5 4> 11700 4 2B 0.000061 4> 1.0 4> 36300 4 3B 0.000096 3> 2.5 3> 46900 3 4B 0.000067 4> 1.0 4> 39400 4 5B 0.00029 3 > 1.0 3> 5770 3 6B 0.00041 3 15 4 28 100 3 7A-D 0.00016 3> 1.0 3> 9330 3 10A 0.00011 6 15 5 131977 5 N = the number of independent experiments in which the compounds were tested.
Table 7: EC50, CC50 and SI for compounds against serotype 3 in RT-qPCR assays RT-qPCR serotype 3 H87 No. of EC50 compound (µM) N CC50 (µM) N SI N 1B 0.0019 4> 2 , 5 4> 1590 4 2B 0.00085 4> 1.0 4> 2050 4 3B 0.0015 3> 2.5 3> 3870 3 4B 0.00092 4> 1.0 4> 2360 4 5B 0.0026 3 > 1.0 3> 719 3 6B 0.0056 4 13 4 2520 4 7A-D 0.0024 3> 1.0 3> 574 3 10A 0.0042 5 15 5 6210 5 N = the number of independent experiments in which the compounds were tested.
Table 8: EC50, CC50 and SI for compounds against serotype 4 in RT-qPCR assays RT-qPCR serotype 4 H241 Compound No. EC50 (µM) N CC50 (µM) N SI N 1B 0.0096 4 8, 8 4 2980 4 2B 0.010 4 4.1 4 1020 4 3B 0.014 3 3.6 1 333 1 4B 0.012 3 6.8 2 563 2 5B 0.020 3 8.4 3 618 3 6B 0.029 4 9.7 3 317 3 7A -D 0.013 3 8.2 3 1000 3 10A 0.030 5 3.2 5 105 5 N = the number of independent experiments in which the compounds were tested.

权利要求:
Claims (11)
[1]
1. Compound of formula (I), characterized by the fact that it includes any stereochemically isomeric form of it, R1 CH3
R2 R3 OH (I)
AT THE
H
AO where R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is pentafluorosulfanyl, R5 is hydrogen, Z is carbon and R6 is hydrogen, or R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethyl, R5 is hydrogen, Z is carbon and R6 is methyl, or R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethyl, R5 is fluorine, Z is carbon and R6 is hydrogen, or R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is methyl, or R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is fluorine, Z is carbon and R6 is hydrogen, or R1 is fluorine, R2 is methoxy, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is hydrogen, or R1 is chlorine, R2 is hydrogen, R3 is deuterium, A is (a-1), R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon and R6 is hydrogen, or R1 is chlorine, R2 is -OCH2CH2OH, R3 is hydrogen, A is (a-1), R4 is trifluoromethoxy, R5 is hi hydrogen, Z is carbon and R6 is hydrogen, or
R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethyl, R5 is methoxy, Z is nitrogen and R6 is absent, or R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-2) and R4 is trifluoromethyl, or R1 is chlorine, R2 is hydrogen, R3 is hydrogen, A is (a-1), R4 is trifluoromethylthio, R5 is hydrogen, Z is carbon and R6 is hydrogen; or a pharmaceutically acceptable salt, solvate or polymorph thereof.
[2]
2. Compound, according to claim 1, characterized by the fact that A is (a-1).
[3]
3. Compound according to claim 1, characterized by the fact that A is (a-2).
[4]
Compound according to any one of claims 1 to 3, characterized by the fact that said compound has a specific rotation (+).
[5]
5. Compound, according to claim 1, characterized by the fact that said compound is selected from: Cl Cl OMe OMe O O (+) F (+) F
F F F N
Y N N
N H H
CUTE
F O O
HO HO Cl Cl OMe OMe O O (+) (+)
F
F N F N
The N H
N H O
F O F
OH F OH
F O
O Cl F OMe OMe MeO O (+) O (+)
F N F N
O N H O N H
O O
CUTE
F F
F
HO HO HO
Cl Cl OMe OMe O D (+) O (+)
N N
F O N H F N H
O O
F OH F O
F S
F
The HO
[6]
6. Pharmaceutical composition, characterized by the fact that it comprises a compound, as defined in any one of claims 1 to 5, together with one or more excipients, diluents or pharmaceutically acceptable vehicles.
[7]
7. Pharmaceutical composition according to claim 6, characterized by the fact that it comprises a second active ingredient or additional active ingredient.
[8]
8. Pharmaceutical composition according to claim 7, characterized by the fact that the second active ingredient or additional active ingredient is an antiviral agent.
[9]
Compound of formula (I) according to any one of claims 1 to 5, characterized in that it is for use as a medicine.
[10]
10. Compound of formula (I) according to any one of claims 1 to 5, characterized in that it is for use in the treatment of Dengue infection and for the prevention or treatment of disease associated with Dengue infection.
[11]
11. Compound of formula (I) for use, according to claim 10, characterized by the fact that Dengue infection is infection by virus of the strain DENV-1, DENV-2, DENV-3 or DENV-4 .

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112019024311A2|2020-07-28|substituted indoline derivatives as dengue viral replication inhibitors

---

ES2884151T3|2021-12-10|Substituted indoline derivatives as inhibitors of dengue virus replication

---

ES2884067T3|2021-12-10|Substituted indoline derivatives as inhibitors of dengue viral replication

---

ES2893298T3|2022-02-08|Mono- or disubstituted indole derivatives as inhibitors of dengue viral replication

---

JP6931357B2|2021-09-01|Substituted indoline derivative as a dengue virus replication inhibitor

---

ES2882488T3|2021-12-02|Substituted indole derivatives as inhibitors of dengue virus replication

---

ES2877404T3|2021-11-16|Mono or disubstituted indole derivatives as inhibitors of dengue viral replication

---

ES2778431T3|2020-08-10|Mono- or disubstituted indole derivatives as inhibitors of dengue viral replication

---

KR102359766B1|2022-02-07|Substituted Indole Compound Derivatives as Dengue Virus Replication Inhibitors

---

ES2887673T3|2021-12-27|Substituted indoline derivatives as inhibitors of dengue viral replication

---

BR112019024195A2|2020-06-23|COMPOUND AND PHARMACEUTICAL COMPOSITION OF INDOLINE DERIVATIVES REPLACED AS INHIBITORS OF DENGUE VIRAL REPLICATION

---

OA19489A|2020-10-23|Substituted indoline derivatives as dengue viral replication inhibitors.

---

OA18876A|2019-09-13|Substituted indoline derivatives as dengue viral replication inhibitors

---

OA18873A|2019-09-13|Substituted indole derivatives as dengue viral replication inhibitors

---

OA19265A|2020-06-05|Substituted indoline derivatives as dengue viral replication inhibitors

同族专利:

---

公开号 | 公开日

---

AR111820A1|2019-08-21|

---

AU2018274101A1|2019-11-07|

---

CL2019003309A1|2020-03-20|

---

MX2019013878A|2020-01-20|

---

HRP20210724T1|2021-10-15|

---

UY37741A|2018-11-30|

---

ES2884157T3|2021-12-10|

---

CO2019013042A2|2020-01-17|

---

JP2020520950A|2020-07-16|

---

LT3630724T|2021-08-25|

---

US11053196B2|2021-07-06|

---

DK3630724T3|2021-07-26|

---

EP3630724B1|2021-04-28|

---

SI3630724T1|2021-08-31|

---

PH12019502577A1|2020-07-20|

---

ECSP19083621A|2019-11-30|

---

EP3630724A1|2020-04-08|

---

CN110753682A|2020-02-04|

---

IL270727D0|2020-01-30|

---

WO2018215316A1|2018-11-29|

---

US20200181083A1|2020-06-11|

---

EA201992784A1|2020-04-23|

---

CA3061026A1|2018-11-29|

---

US20210300868A1|2021-09-30|

---

TW201900611A|2019-01-01|

---

PE20200342A1|2020-02-14|

---

KR20200010355A|2020-01-30|

---

CR20190531A|2020-03-05|

---

HUE054379T2|2021-09-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US6177426B1|1997-10-27|2001-01-23|Eli Lilly And Company|Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors|

---

GB0110832D0|2001-05-03|2001-06-27|Virogen Ltd|Antiviral compounds|

---

US20050074457A1|2001-12-12|2005-04-07|Adeela Kamal|Assays and implements for determining and modulating hsp90 binding activity|

---

GB0215293D0|2002-07-03|2002-08-14|Rega Foundation|Viral inhibitors|

---

KR20070098914A|2005-01-14|2007-10-05|제네랩스 테크놀로지스, 인코포레이티드|Indole derivatives for treating viral infections|

---

CA2597213A1|2005-02-09|2006-09-14|Migenix Inc.|Compositions and methods for treating or preventing flaviviridae infections|

---

EP2293671A4|2008-06-03|2012-03-21|Siga Technologies Inc|Small molecule inhibitors for the treatment or prevention of dengue virus infection|

---

US8143259B2|2008-08-19|2012-03-27|Janssen Pharmaceutica, Nv|Cold menthol receptor antagonists|

---

TWI453207B|2008-09-08|2014-09-21|Signal Pharm Llc|Aminotriazolopyridines, compositions thereof, and methods of treatment therewith|

---

WO2010091413A1|2009-02-09|2010-08-12|Enanta Pharmaceuticals, Inc.|Linked dibenzimidazole derivatives|

---

GB0910003D0|2009-06-11|2009-07-22|Univ Leuven Kath|Novel compounds for the treatment of neurodegenerative diseases|

---

US8993604B2|2009-06-30|2015-03-31|Siga Technologies, Inc.|Treatment and prevention of dengue virus infections|

---

US7948798B1|2009-07-22|2011-05-24|Marvell International Ltd.|Mixed multi-level cell and single level cell storage device|

---

EA201290575A1|2010-01-15|2013-01-30|Джилид Сайэнс, Инк.|FLAVIVIRIDAE VIRUS INHIBITORS|

---

JP2013523657A|2010-03-26|2013-06-17|グラクソグループリミテッド|Indazolyl-pyrimidine as a kinase inhibitor|

---

JP5716205B2|2011-03-29|2015-05-13|学校法人日本大学|Composition for inhibiting glucosidase activity and screening method thereof|

---

GB201116559D0|2011-09-26|2011-11-09|Univ Leuven Kath|Novel viral replication inhibitors|

---

GB201305376D0|2013-03-25|2013-05-08|Univ Leuven Kath|Novel viral replication inhibitors|

---

EP3060547B1|2013-10-23|2017-10-11|Janssen Sciences Ireland UC|Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b|

---

SG10201908467RA|2014-01-31|2019-10-30|Squibb Bristol Myers Co|Macrocycles with hetrocyclic p2' groups as factor xia inhibitors|

---

NO2721243T3|2014-10-01|2018-10-20|

---

EA032546B1|2014-10-01|2019-06-28|Янссен Фармасьютикалз, Инк.|Mono- or disubstituted indole derivatives as dengue viral replication inhibitors|

---

ME03344B|2014-10-01|2019-10-20|Janssen Pharmaceuticals Inc|Mono- or di-substituted indoles as dengue viral replication inhibitors|

---

MA41341A|2015-01-16|2017-11-21|Janssen Pharmaceuticals Inc|INDOLE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS|

---

AR103680A1|2015-02-23|2017-05-24|Lilly Co Eli|BACE1 SELECTIVE INHIBITORS|

---

US10696632B2|2015-05-08|2020-06-30|Janssen Pharmaceuticals, Inc.|Mono- or di-substituted indole derivatives as dengue viral replication inhibitors|

---

KR20180052672A|2015-09-16|2018-05-18|얀센 파마슈티칼즈, 인코포레이티드|1- or 2-substituted indole derivatives as Dengue virus replication inhibitors|

---

JO3633B1|2015-09-16|2020-08-27|Katholieke Univ Leuven Ku Leuven Research & Development|Mono- or di-substituted indole derivatives as dengue viral replication inhibitors|

---

MX2018005547A|2015-11-03|2018-11-09|Zoetis Services Llc|Sol-gel polymer composites and uses thereof.|

---

SI3436435T1|2016-03-31|2021-08-31|Janssen Pharmaceuticals, Inc.|Substituted indole derivatives as dengue viral replication inhibitors|

---

MX2018011729A|2016-03-31|2019-01-10|Takeda Pharmaceuticals Co|Heterocyclic compound.|

---

CA3013407A1|2016-03-31|2017-10-05|Janssen Pharmaceuticals, Inc.|Substituted indoline derivatives as dengue viral replication inhibitors|

---

SG11201808622SA|2016-04-01|2018-10-30|Amgen Inc|Chimeric receptors to flt3 and methods of use thereof|

---

AR108046A1|2016-04-01|2018-07-11|Janssen Pharmaceuticals Inc|INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE|

---

MX2018012017A|2016-04-01|2019-07-04|Kite Pharma Inc|Chimeric antigen and t cell receptors and methods of use.|

---

PE20181898A1|2016-04-01|2018-12-11|Basf Se|BICYCLE COMPOUNDS|

---

CA3018986A1|2016-04-01|2017-10-05|Signal Pharmaceuticals, Llc|Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith|

---

JP2019513370A|2016-04-01|2019-05-30|カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａ|Chimeric receptor and method of using the same|

---

SG11201808237UA|2016-04-01|2018-10-30|Janssen Pharmaceuticals Inc|Substituted indole compound derivatives as dengue viral replication inhibitors|

---

JOP20180026A1|2017-03-31|2019-01-30|Univ Leuven Kath|Substituted indoline derivatives as dengue viral replication inhibitors|

---

JOP20180025A1|2017-03-31|2019-01-30|Janssen Pharmaceuticals Inc|Substituted indoline derivatives as dengue viral replication inhibitors|

---

US20200255376A1|2017-05-22|2020-08-13|Janssen Pharmaceuticals, Inc.|Substituted indoline derivatives as dengue viral replication inhibitors|GB201116559D0|2011-09-26|2011-11-09|Univ Leuven Kath|Novel viral replication inhibitors|

---

US10696632B2|2015-05-08|2020-06-30|Janssen Pharmaceuticals, Inc.|Mono- or di-substituted indole derivatives as dengue viral replication inhibitors|

---

JO3633B1|2015-09-16|2020-08-27|Katholieke Univ Leuven Ku Leuven Research & Development|Mono- or di-substituted indole derivatives as dengue viral replication inhibitors|

---

KR20180052672A|2015-09-16|2018-05-18|얀센 파마슈티칼즈, 인코포레이티드|1- or 2-substituted indole derivatives as Dengue virus replication inhibitors|

---

CA3013407A1|2016-03-31|2017-10-05|Janssen Pharmaceuticals, Inc.|Substituted indoline derivatives as dengue viral replication inhibitors|

---

SI3436435T1|2016-03-31|2021-08-31|Janssen Pharmaceuticals, Inc.|Substituted indole derivatives as dengue viral replication inhibitors|

---

SG11201808237UA|2016-04-01|2018-10-30|Janssen Pharmaceuticals Inc|Substituted indole compound derivatives as dengue viral replication inhibitors|

---

AR108046A1|2016-04-01|2018-07-11|Janssen Pharmaceuticals Inc|INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE|

---

JOP20180025A1|2017-03-31|2019-01-30|Janssen Pharmaceuticals Inc|Substituted indoline derivatives as dengue viral replication inhibitors|

---

JOP20180026A1|2017-03-31|2019-01-30|Univ Leuven Kath|Substituted indoline derivatives as dengue viral replication inhibitors|

---

JP2021529159A|2018-06-19|2021-10-28|ノバルティス アーゲー|N-Substituted Tetrahydrothienopyridine Derivatives and Their Use|

---

JP2022516883A|2018-12-27|2022-03-03|レ ラボラトワール セルヴィエ エスアーエス|Mat2A aza complex bicyclic inhibitor and its use for the treatment of cancer|

法律状态:
2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

EP17172247|2017-05-22|

---

EP17172247.3|2017-05-22|

---

PCT/EP2018/063029|WO2018215316A1|2017-05-22|2018-05-18|Substituted indoline derivatives as dengue viral replication inhibitors|

---